<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106096</article-id><article-id pub-id-type="doi">10.7554/eLife.106096</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106096.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Affinity-guided labeling reveals P2X7 nanoscale membrane redistribution during BV2 microglial activation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arnould</surname><given-names>Benoit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Martz</surname><given-names>Adeline</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-4751-2587</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Belzanne</surname><given-names>Pauline</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Peralta</surname><given-names>Francisco Andrés</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0727-1706</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cevoli</surname><given-names>Federico</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hovhannisyan</surname><given-names>Volodya</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Goumon</surname><given-names>Yannick</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hosy</surname><given-names>Eric</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2479-5915</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Specht</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Grutter</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4351-9203</contrib-id><email>grutter@unistra.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rh71z37</institution-id><institution>Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST) UMR 7199, équipe Ingénierie Canaux Ioniques, Centre National de la Recherche Scientifique, Université de Strasbourg, Faculté de Pharmacie</institution></institution-wrap><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057qpr032</institution-id><institution>Interdisciplinary Institute for Neuroscience, CNRS, Université de Bordeaux</institution></institution-wrap><addr-line><named-content content-type="city">Bordeaux</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pg6eq24</institution-id><institution>University of Strasbourg Institute for Advanced Studies (USIAS)</institution></institution-wrap><addr-line><named-content content-type="city">Strasbourg</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/025mhd687</institution-id><institution>Centre National de la Recherche Scientifique-Unité Propre de Recherche (CNRS-UPR) 3212, Institut des Neurosciences Cellulaires et Intégratives</institution></institution-wrap><addr-line><named-content content-type="city">Strasbourg</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pg6eq24</institution-id><institution>Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST) UMR 7199, équipe NanoParticules Intelligentes, Centre National de la Recherche Scientifique, Université de Strasbourg</institution></institution-wrap><addr-line><named-content content-type="city">Strasbourg</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pless</surname><given-names>Stephan A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>University of Copenhagen</institution></institution-wrap><country>Denmark</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s5ya894</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>CNRS UMR9187, INSERM U1196, Institut Curie, PSL Research University, Orsay, France</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>09</day><month>01</month><year>2026</year></pub-date><volume>14</volume><elocation-id>RP106096</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-01-24"><day>24</day><month>01</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-01-28"><day>28</day><month>01</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.01.24.634652"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-30"><day>30</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106096.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-12-15"><day>15</day><month>12</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106096.2"/></event></pub-history><permissions><copyright-statement>© 2025, Arnould et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Arnould et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106096-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-106096-figures-v1.pdf"/><abstract><p>ATP-gated purinergic P2X7 receptors are crucial ion channels involved in inflammation. They sense abnormal ATP release during stress or injury and are considered promising clinical targets for therapeutic intervention. However, despite their predominant expression in immune cells such as microglia, there is limited information on P2X7 membrane expression and regulation during inflammation at the single-molecule level, necessitating new labeling approaches to visualize P2X7 in native cells. Here, we present <bold>X7-uP</bold>, an unbiased, affinity-guided P2X7 chemical labeling reagent that selectively and covalently biotinylates endogenous P2X7 in BV2 cells, a murine microglial cell line, allowing subsequent labeling with streptavidin-Alexa 647 tailored for super-resolution imaging. We uncovered a nanoscale microglial P2X7 redistribution mechanism where evenly spaced individual receptors in quiescent cells undergo upregulation and clustering in response to the pro-inflammatory agent lipopolysaccharide and ATP, leading to synergistic interleukin-1β release. Our method thus offers a new approach to revealing endogenous P2X7 expression at the single-molecule level.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mouse BV2 cells</kwd><kwd>human HEK293T cells</kwd><kwd>rat P2X sequences</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rbzpz17</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-20-CE14-0016-2</award-id><principal-award-recipient><name><surname>Grutter</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tscbz39</institution-id><institution>International Center for Frontier Research in Chemistry</institution></institution-wrap></funding-source><award-id>Labex CSC-TGR-18</award-id><principal-award-recipient><name><surname>Peralta</surname><given-names>Francisco Andrés</given-names></name><name><surname>Grutter</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tscbz39</institution-id><institution>International Center for Frontier Research in Chemistry (Labex CSC-TGR-18) and Région Grand Est</institution></institution-wrap></funding-source><award-id>PhD grant</award-id><principal-award-recipient><name><surname>Cevoli</surname><given-names>Federico</given-names></name><name><surname>Grutter</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03sjk9a61</institution-id><institution>Ministere de la Recherche</institution></institution-wrap></funding-source><award-id>PhD grant</award-id><principal-award-recipient><name><surname>Arnould</surname><given-names>Benoit</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pg6eq24</institution-id><institution>University of Strasbourg Institute for Advanced Study</institution></institution-wrap></funding-source><award-id>USIAS 2019</award-id><principal-award-recipient><name><surname>Peralta</surname><given-names>Francisco Andrés</given-names></name><name><surname>Grutter</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Interdisciplinary Thematic Institute NeuroStra</institution></institution-wrap></funding-source><award-id>ANR-17-EURE-0022</award-id><principal-award-recipient><name><surname>Arnould</surname><given-names>Benoit</given-names></name><name><surname>Grutter</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An affinity-guided chemical strategy enabling highly specific biotinylation of P2X7 receptors reveals, by super-resolution microscopy, how the nanoscale organization of endogenous P2X7 in BV2 microglial cells dynamically changes upon activation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>ATP serves as the primary energy carrier in cells and also functions as an extracellular signaling molecule. Normally, extracellular ATP levels are typically low in healthy interstitial fluid, but they rise at sites of stress or cellular injury, acting as a danger signal recognized as a damage-associated molecular pattern (DAMP). Extracellular ATP is detected by two families of purinergic receptors, metabotropic P2Y receptors and ionotropic P2X receptors (P2X1 to P2X7), with P2X7 specifically sensing abnormal ATP release in the mid-micromolar to low millimolar range (<xref ref-type="bibr" rid="bib8">Burnstock, 2004</xref>; <xref ref-type="bibr" rid="bib37">Jacobson et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Illes et al., 2021</xref>). P2X7 is a transmembrane, non-selective cation channel (Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>) predominantly expressed in immune cells, such as macrophages and microglia (the resident macrophages of the central nervous system), where it plays a crucial role in inflammation and immunity (<xref ref-type="bibr" rid="bib54">North, 2002</xref>; <xref ref-type="bibr" rid="bib13">Di Virgilio et al., 2017</xref>). Upon ATP binding, P2X7 activation triggers K<sup>+</sup> efflux, promoting the assembly of the NLRP3 inflammasome and leading to the maturation and secretion of pro-inflammatory mediators, including interleukin-1β (IL-1β; <xref ref-type="bibr" rid="bib18">Ferrari et al., 1996</xref>; <xref ref-type="bibr" rid="bib19">Ferrari et al., 1997</xref>; <xref ref-type="bibr" rid="bib52">Monif et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Bhattacharya and Biber, 2016</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Illes, 2020</xref>). P2X7 activation can cause cell death and is linked to the pathogenesis of several major disorders, including inflammatory pain (<xref ref-type="bibr" rid="bib36">Inoue and Tsuda, 2021</xref>), autoimmune diseases (<xref ref-type="bibr" rid="bib10">Cao et al., 2019</xref>), tumor progression (<xref ref-type="bibr" rid="bib41">Kan et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Douguet et al., 2021</xref>), psychiatric conditions (<xref ref-type="bibr" rid="bib30">Huang and Tan, 2021</xref>), anxiety-like behavior (<xref ref-type="bibr" rid="bib31">Huang et al., 2024</xref>), and neurodegenerative diseases (<xref ref-type="bibr" rid="bib71">Volonté et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Martin et al., 2019</xref>), making P2X7 a clinically relevant target.</p><p>At the cellular level, P2X7 is expressed at the plasma membrane and associates with lipid rafts, which are membrane microdomains known to play a key role in the onset of inflammation (<xref ref-type="bibr" rid="bib23">Garcia-Marcos et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">García-Marcos et al., 2006</xref>; <xref ref-type="bibr" rid="bib3">Barth et al., 2007</xref>; <xref ref-type="bibr" rid="bib4">Barth et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Gonnord et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Weinhold et al., 2010</xref>). However, it is unknown how P2X7 is strictly distributed on the plasma membrane of cells and how its spatial and functional features intertwine in inflammatory conditions. Given the crucial role of P2X7 in inflammation and the growing interest in developing P2X7-targeted therapeutics, new approaches are needed to visualize P2X7 expression in immune cells at the single molecule level.</p><p>Numerous studies have investigated P2X7 expression in microglia using various experimental approaches, including functional assays (<xref ref-type="bibr" rid="bib18">Ferrari et al., 1996</xref>; <xref ref-type="bibr" rid="bib58">Raouf et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Janks et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Trang et al., 2020</xref>), radiolabeled ligand binding (<xref ref-type="bibr" rid="bib45">Lord et al., 2015</xref>), immunofluorescence staining (<xref ref-type="bibr" rid="bib11">Choi et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Monif et al., 2009</xref>), electron microscopy (<xref ref-type="bibr" rid="bib53">Monif et al., 2016</xref>), and genetic manipulations (<xref ref-type="bibr" rid="bib40">Kaczmarek-Hajek et al., 2018</xref>). Although these studies confirmed the dominant expression of P2X7 in microglia, they provided only low-resolution cell imaging of P2X7, primarily due to the limitations of conventional light microscopy, which imposes a resolution restricted by the diffraction of light. Consequently, the detailed organization of P2X7 below ~250 nm remains unknown. This is a vital point, as recent data suggest that the spatial organization of cell membrane receptors may be a common regulatory mechanism for cellular signal transduction (<xref ref-type="bibr" rid="bib46">Manz and Groves, 2010</xref>). However, it remains unclear whether such membrane organization similarly affects P2X7 signaling pathways.</p><p>Super-resolution microscopy techniques overcome this diffraction limit, enabling the visualization of fluorescently labeled membrane receptors at nanometric resolution (<xref ref-type="bibr" rid="bib60">Schermelleh et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Choquet et al., 2021</xref>). To the best of our knowledge, only two studies have reported super-resolved images of P2X7 (<xref ref-type="bibr" rid="bib62">Shrivastava et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Gangadharan et al., 2015</xref>). The first study found P2X7 in lipid microdomains of an osteoblastic cell line (<xref ref-type="bibr" rid="bib22">Gangadharan et al., 2015</xref>), but the use of polyclonal antibodies to stain P2X7 raised questions about their selectivity (<xref ref-type="bibr" rid="bib39">Kaczmarek-Hájek et al., 2012</xref>). The second study involved fusing P2X7 to the photo-convertible fluorescent Dendra2 protein to track its dynamic organization in hippocampal neurons (<xref ref-type="bibr" rid="bib62">Shrivastava et al., 2013</xref>). While this study provided valuable insights into the nanometer-scale distribution of P2X7, it had three experimental biases. First, heterologous overexpression of P2X7-Dendra2 might not reflect native expression levels. Second, the C-terminal fusion of Dendra2 to P2X7 after the ‘ballast’ (<xref ref-type="bibr" rid="bib48">McCarthy et al., 2019</xref>), a region that is critically involved in inflammation (<xref ref-type="bibr" rid="bib13">Di Virgilio et al., 2017</xref>), could affect P2X7’s pathogenicity. Third, there is growing evidence suggesting that neurons do not (or scarcely) express P2X7 (<xref ref-type="bibr" rid="bib40">Kaczmarek-Hajek et al., 2018</xref>), questioning the physiological relevance of investigating P2X7 nanoscale organization in hippocampal neurons. Therefore, these issues prompted us to develop a new, genetic-free strategy able to decorate endogenous P2X7 in native cells with fluorophores suitable for super-resolution imaging.</p><p>Among existing methods for labeling endogenous proteins in living cells, the affinity-driven reaction strategy involving protein-ligand interaction is of particular interest (<xref ref-type="bibr" rid="bib61">Shiraiwa et al., 2020</xref>). It relies on the formation of a covalent bond on the protein that is guided by the affinity of a ligand bearing a reactive chemical moiety. The efficiency of the labeling reaction depends on the chemical function of the reactive species. The recently developed <italic>N</italic>-acyl-<italic>N</italic>-alkyl sulfonamide (NASA) chemistry offers a suitable platform that enables the covalent transfer, under native cell conditions, of functional ligands to nucleophilic amino acid residues (typically lysine residues) located in close proximity to the ligand-binding site (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). In addition, NASA electrophilicity can be finely tuned by introducing an electron-withdrawing moiety to the <italic>N</italic>-alkyl group, such as cyanomethyl, so that kinetic labeling can be considerably enhanced and carried out within minutes under physiological conditions (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Affinity-guided labeling strategy for P2X7.</title><p>(<bold>A</bold>) Schematic representation of the P2X7 labeling strategy using ligand-directed <italic>N</italic>-cyanomethyl NASA chemistry. A P2X7 ligand (Lg) binds to allosteric sites on the receptor, bringing the <italic>N</italic>-cyanomethyl NASA warhead into close proximity with endogenous lysine (K) residues. This spatial arrangement enables the covalent transfer of a biotin moiety via amide bond formation, resulting in highly specific biotinylation of P2X7. The biotin tag allows super-resolution imaging of nanoscale P2X7 localization using a Streptavidin-Alexa 647 probe (Strept-A 647). Notably, following biotin transfer, the ligand can dissociate from P2X7, leaving the allosteric sites unoccupied. (<bold>B</bold>) Crystal structure of panda P2X7 (pdP2X7) shown in ribbon representation, bound to AZ10606120 depicted as spheres (PDB:5U1W; <xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). One of the three ATP-binding sites and the approximate location of the membrane are also indicated. Inset, enlarged view of the AZ10606120-binding pocket, rotated 180°. Distances (in Å) between the α-carbon of selected lysines and the hydroxyl group of AZ10606120 are displayed. Note that K300 is not visible in this view. (<bold>C</bold>) Chemical structure of <bold>X7-uP</bold>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Mapping the X7-uP labeling site.</title><p>(<bold>A</bold>) Sequence alignment of selected regions from P2X receptors: panda P2X7 (pdP2X7), rat P2X7 (rP2X7), mouse P2X7 (mP2X7), human P2X7 (hP2X7), and rat and human P2X1–6 (rP2X1–6, hP2X1–6). Lysine residues are highlighted in red. Secondary structure elements are depicted in cartoon representation and are labeled as in the crystal structure of pdP2X7 (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). (<bold>B</bold>) Chemical structures of compound <bold>1</bold> and AZ10606120. Red star indicates electrophilic carbon of the <italic>N</italic>-cyanomethyl NASA reacting group. (<bold>C</bold>) Right, crystal structure of AZ10606120 (stick representation) bound to pdP2X7 (PDB:5 U1W) (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). Left, same view with <bold>1</bold> docked to pdP2X7 (left). Distances (in Å) separating the reactive carbonyl of <bold>1</bold> and selected α-carbons of nearby residues (red stick) are shown, along with residues (blue stick) important for AZ10606120 binding (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). Residues shown in parentheses are the equivalent rat P2X7 residues.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Multi-step synthesis of X7-uP.</title><p>1,2-DCE: 1,2-dichloroethane; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBt: 1-Hydroxybenzotriazole; DIEA: N,N-Diisopropylethylamine; DMAP: 4-Dimethylaminopyridine; DMTMM: 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)–4-methyl-morpholinium chloride.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title><sup>1</sup>H NMR spectrum of compound 3.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title><sup>1</sup>H NMR spectrum of compound 5.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title><sup>1</sup>H NMR spectrum of compound 6.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title><sup>1</sup>H NMR spectrum of compound 7.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>NMR spectra of compound 8.</title><p><sup>1</sup>H NMR (<bold>A</bold>) and <sup>13</sup>C NMR (<bold>B</bold>) spectra of compound 8.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 8.</label><caption><title>NMR spectra of compound 10.</title><p><sup>1</sup>H NMR (<bold>A</bold>) and <sup>13</sup>C NMR (<bold>B</bold>) spectra of compound 10.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 9.</label><caption><title>NMR spectra of compound 11.</title><p><sup>1</sup>H NMR (<bold>A</bold>) and <sup>13</sup>C NMR (<bold>B</bold>) spectra of compound 11.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 10.</label><caption><title>NMR spectra of compound X7-uP.</title><p><sup>1</sup>H NMR (<bold>A</bold>) and <sup>13</sup>C NMR (<bold>B</bold>) spectra of compound X7-uP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig1-figsupp10-v1.tif"/></fig></fig-group><p>Here, we report <bold>X7-uP</bold>, a P2<bold>X7-u</bold>nbiased <bold>P</bold>urinergic labeling reagent that efficiently biotinylates native P2X7 lysine residues via a <italic>N</italic>-cyanomethyl NASA-based chemical reaction driven by the affinity of AZ10606120, a highly selective P2X7 allosteric ligand. Using streptavidin-Alexa Fluor 647 (Strept-A 647), we reveal the nanoscale distribution of P2X7 in BV2 cells at the single molecule level by direct stochastic optical-reconstruction microscopy (dSTORM). We show that P2X7 is homogenously dispersed on the plasma membrane as single receptors in quiescent (non-inflammatory condition) cells. However, upon exposure to the pro-inflammatory agent lipopolysaccharide (LPS), a pathogen-associated molecular pattern (PAMP) from Gram-negative bacteria, combined with ATP or its potent synthetic analog BzATP, P2X7 undergoes significant upregulation and clustering, resulting in the synergistic release of IL-1β. Our findings suggest that the dynamic clustering of P2X7 on the plasma membrane is a crucial mechanism underlying IL-1β secretion.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Design and synthesis of X7-uP</title><p><bold>X7-uP</bold> was rationally designed by leveraging available X-ray structures of the panda P2X7 receptor (pdP2X7) bound to non-competitive P2X7 antagonists (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). These antagonists bind to an interfacial allosteric binding pocket in pdP2X7, distinct from ATP-binding sites, and accessible from the upper side of the trimeric receptor (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). Due to the trimeric assembly of P2X subunits, three allosteric binding sites are present in P2X7 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We focused on AZ10606120, a selective antagonist with high affinity for human (hP2X7) and rat P2X7 (rP2X7), with no effect on other P2X receptors (<xref ref-type="bibr" rid="bib49">Michel et al., 2007</xref>; <xref ref-type="bibr" rid="bib27">Guile et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Bhattacharya et al., 2013</xref>; <xref ref-type="bibr" rid="bib1">Allsopp et al., 2017</xref>). The X-ray structure revealed several lysine residues localized in proximity to AZ10606120 (&lt;15 Å, measured from α-carbon of K72, K81, K82, K110, and K300, and the solvent-exposed hydroxyl of AZ10606120) (<xref ref-type="fig" rid="fig1">Figure 1B</xref> inset). Since most of these lysine residues are unique to P2X7 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), we hypothesized that NASA chemistry could selectively label P2X7. We modified AZ10606120 by replacing its solvent-exposed hydroxyethyl group with the reactive <italic>N</italic>-cyanomethyl NASA derivative, allowing a labeling reaction with the ε-amino group of nearby P2X7 lysine residues, forming a stable amide bond (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We used molecular docking to identify molecule <bold>1</bold> as a promising molecular scaffold built from AZ10606120 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). The distance separating the NASA electrophilic carbon of <bold>1</bold> and each α-carbon of nearby P2X7 residues was compatible with a proximity-driven reaction with rP2X7 (≤16.1 Å, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), the receptor species used to experimentally validate the approach (see below). Thus, we designed and synthesized <bold>X7-uP</bold>, an extended version of <bold>1</bold>, containing an OEG (oligoethylene glycol) biotin tag (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). <bold>X7-uP</bold> is expected to covalently transfer the biotin tag to P2X7, which, in turn, can serve as a versatile platform for subsequent cell surface labeling with commercially available, cell-impermeable biotin-binding protein-conjugated molecular probes, including Alexa 647, suitable for super-resolution microscopy (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). <bold>X7-uP</bold> was synthesized as described in Materials and methods (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p></sec><sec id="s2-2"><title>X7-uP inhibits and biotinylates heterologously expressed rP2X7 in HEK293T cells</title><p>To address possible loss of affinity due to chemical modifications of the pharmacophore, we first assessed the ability of <bold>X7-uP</bold> to bind to P2X7 by measuring agonist-evoked current inhibition using whole-cell patch-clamp electrophysiology. In HEK293T cells transiently transfected with rP2X7, we recorded inward currents induced by eight successive applications of 10 µM 2'(3')-<italic>O</italic>-(4-benzoylbenzoyl)ATP (BzATP), a potent P2X7 agonist (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). As expected, currents facilitated upon successive BzATP applications, a hallmark feature of P2X7 (<xref ref-type="bibr" rid="bib67">Surprenant et al., 1996</xref>). Application of 1 µM of <bold>X7-uP</bold> for 10 s after washout of the fourth BzATP application did not induce inward currents but strongly inhibited currents induced by co-application for 2 s with BzATP (79.3 ± 5.6%, mean ± standard error of the mean (s.e.m.), n=4; control without inhibitors: –15.2 ± 4.4%, n=4, <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Inhibition was reversible, as BzATP-evoked currents fully restored upon <bold>X7-uP</bold> washout (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Compared to the parental AZ10606120 compound, which produced nearly complete inhibition at 1 µM (99.7 ± 0.1%, n=4, <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>), the strong but incomplete inhibition observed with <bold>X7-uP</bold> suggests that the chemical modification reduces its inhibitory potency at P2X7. To quantify this effect, we compared inhibition by 300 µM <bold>X7-uP</bold> with that produced by 10 nM AZ10606120, a concentration close to its reported IC<sub>50</sub> (<xref ref-type="bibr" rid="bib5">Bhattacharya et al., 2013</xref>). Under these conditions, <bold>X7-uP</bold> produced a similar level of inhibition (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), indicating that although its potency is markedly reduced relative to AZ10606120, it nonetheless remains an effective P2X7 probe at 1 μM.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>X7-uP is a potent P2X7 inhibitor that rapidly labels ectopically expressed P2X7 in HEK293T cells.</title><p>(<bold>A</bold>) Whole-cell currents evoked by 10 µM BzATP are reversibly inhibited by co-applying 1 µM <bold>X7-uP</bold> (upper trace) or 1 µM AZ10606120 (middle trace) in cells transiently transfected with rP2X7. Inhibitors were pre-applied alone for 10 s before 2 s of co-application. In the control (absence of inhibitors), BzATP-induced currents further increased, demonstrating current facilitation, which is an expected feature of P2X7 activation (<xref ref-type="bibr" rid="bib67">Surprenant et al., 1996</xref>). (<bold>B</bold>) Summary of whole-cell inhibition at the indicated concentrations (n=4–8 cells for each condition). Bars represent mean ± s.e.m. (<bold>C</bold>) Western blot analysis of P2X7 labeling by <bold>X7-uP</bold>. Cells transiently transfected with P2X7c-myc were treated with 1 µM <bold>X7-uP</bold> for 0–60 minutes, in the absence or presence of 10 µM AZ10606120 or 10 µM A740003 (as indicated), followed by extensive washing. After cell lysis, biotinylated proteins were pulled down, separated on SDS-PAGE, and Western blotting was revealed using an anti-c-myc antibody (@c-myc). Molecular mass markers are shown on the right. Control of P2X7c-myc expression is presented in the corresponding input. β-Actin was used as a loading control. (<bold>D</bold>) Time course plot of P2X7 labeling with 1 µM <bold>X7-uP</bold>. Data (mean ± s.e.m., n=3 independent transfections) were fitted with <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> to determine the pseudo-first-order reaction rate <italic>k</italic><sub>app</sub> (mean ± s.e.m.).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>PDF file containing the original western blots used for <xref ref-type="fig" rid="fig2">Figure 2C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original image files of western blots used for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig2">Figure 2B and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Specificity and kinetic analysis of P2X7 labeling by X7-uP.</title><p>(<bold>A</bold>) Western blot analysis showing the specificity of P2X7 labeling by <bold>X7-uP</bold> in untransfected (-) or P2X7c-myc-transfected (+) HEK293T cells (refer to <xref ref-type="fig" rid="fig2">Figure 2C</xref> for details). Molecular mass markers are shown on the right. (<bold>B</bold>) Western blot analysis of P2X7 labeling using different concentrations of <bold>X7-uP</bold> at various time points in HEK293T cells expressing P2X7c-myc. β-Actin was used as a loading control. Molecular mass markers are shown on the right. (<bold>C</bold>) Time course of P2X7 labeling using 0.5 µM and 2.5 µM <bold>X7-uP</bold>. Data (mean ± s.e.m., n=3 independent transfections) were fitted using <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, providing pseudo-first-order reaction rate constants (<italic>k</italic><sub>app</sub>) (mean ± s.e.m.). (<bold>D</bold>) Concentration-dependence of <italic>k</italic><sub>app</sub> values for <bold>X7-uP</bold>. Data were fitted with <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>, yielding the labeling rate constant (<italic>k</italic><sub>L</sub> = 0.011 ± 0.003 s<sup>–1</sup>, mean of triplicate ± standard deviation (s.d.)) and the dissociation constant (<italic>K</italic><sub>d</sub> = 7.3 ± 2.7 µM, mean ± s.d.).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots used for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original image files of western blots used for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig2-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Determination of X7-uP-induced P2X7 labeling yields in HEK293T and BV2 cells.</title><p>(<bold>A</bold>) Western blot analysis of P2X7 in the supernatants of cell lysates from P2X7c-myc-transfected HEK293T cells (left) or BV2 cells (right), either untreated (-) or treated with <bold>X7-uP</bold> (+) for 60 minutes (HEK293T cells) or 10 minutes (BV2 cells). P2X7 was detected using either an anti-c-myc antibody (for HEK293T cells) or a mouse anti-P2X7 antibody (for BV2 cells). β-Actin was used as a loading control. Molecular mass markers are shown on the right. (<bold>B</bold>) Quantification of P2X7 labeling yield, calculated using the following equation: <inline-formula><alternatives><mml:math id="inf1"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>a</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft1">\begin{document}$\left (1- a/b\right)\times 100$\end{document}</tex-math></alternatives></inline-formula>, where <italic>a</italic> and <italic>b</italic> represent the amounts of P2X7 in lanes 2 and 1 of the supernatants, respectively.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>PDF file containing the original western blots used for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Original image files of western blots used for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata3"><label>Figure 2—figure supplement 2—source data 3.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig2-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig2-figsupp2-v1.tif"/></fig></fig-group><p>To test labeling efficiency, HEK293T cells were transiently transfected with c-myc tagged rP2X7 (P2X7c-myc) and incubated at 20 °C with 1 µM <bold>X7-uP</bold> for 60 min. <bold>X7-uP</bold> labeling was performed under physiological conditions (1 µM for 10 min at 37 °C in FBS-free DMEM, see Materials and methods), followed by extensive washing to remove excess <bold>X7-uP</bold>. After cell lysis, biotinylated proteins were pulled down with NeutrAvidin Agarose, separated on SDS-PAGE, and revealed with an anti-c-myc antibody in western blot analysis. A strong and unique band was detected in the western blot at the expected apparent molecular mass of monomeric P2X7c-myc (~75–80 kDa; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). However, this band disappeared upon co-incubation with AZ10606120 (10 µM), or in the absence of <bold>X7-uP</bold> (lane 1), while robust signals corresponding to P2X7c-myc and β-actin expression were still detected in the corresponding input controls (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Similarly, no signal was detected in non-transfected cells treated with <bold>X7-uP</bold> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). To further demonstrate the pharmacological specificity of P2X7 labeling by <bold>X7-uP</bold>, we used another non-competitive P2X7 antagonist, A740003 (10 µM), which targets the same allosteric binding cavity as AZ10606120 in pdP2X7 but is chemically different from AZ10606120 (<xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). As expected, no labeling was detected when A740003 was co-incubated with <bold>X7-uP</bold> (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Taken together, these data strongly suggest that <bold>X7-uP</bold> biotinylates P2X7 residues by targeting the unique P2X7 allosteric binding site.</p><p>We next conducted a kinetic analysis of P2X7 labeling by incubating cells with <bold>X7-uP</bold> at different concentrations and monitoring labeling through quantitative Western blotting analysis. The time course of P2X7 labeling at 1 µM of <bold>X7-uP</bold> is shown in <xref ref-type="fig" rid="fig2">Figure 2C and D</xref>, with labeled bands detected as early as 5 minutes of incubation time. The data were fitted to <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, derived according to a kinetic model in which an irreversible chemical reaction follows a reversible ligand binding reaction in a large excess of ligand (see Methods) (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>), providing the pseudo-first-order reaction rate (<italic>k</italic><sub>app</sub>) of the labeling reaction. Kinetics of labeling carried out at different <bold>X7-uP</bold> concentrations allowed us to plot <italic>k</italic><sub>app</sub> values against <bold>X7-uP</bold> concentrations (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–D</xref>). The data were fitted to <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>, providing the labeling rate constant <italic>k</italic><sub>L</sub> (0.011±0.003 s<sup>–1</sup>, mean of triplicate ± standard deviation (s.d.)), the dissociation constant <italic>K</italic><sub>d</sub> (7.3±2.7 µM, mean ± s.d.), and the second-order rate constant (<italic>k</italic><sub>L</sub>/ <italic>K</italic><sub>d</sub> = 1.5 × 10<sup>3</sup> M<sup>–1</sup>s<sup>–1</sup>). The second-order rate constant value was comparable to those of previously described labeling reagents based on NASA chemistry (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>).</p><p>Next, we determined <bold>X7-uP</bold> labeling yield by quantifying the amount of P2X7c-myc in the supernatant after pulling down biotinylated P2X7c-myc (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). This amount, corresponding to unbiotinylated P2X7c-myc, was then compared to the maximal amount of unbiotinylated P2X7c-myc carried out in the absence of <bold>X7-uP</bold>, thus providing labeling yield. Quantitative Western blotting analysis revealed that 65 ± 3% (mean of triplicate ± s.e.m.) of P2X7c-myc were labeled by 1 µM of <bold>X7-uP</bold> for 60 min in HEK293T cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>).</p></sec><sec id="s2-3"><title>X7-uP labeling is selective for P2X7</title><p>Having established the efficacy of P2X7 labeling by Western blot, we next assessed the selectivity of <bold>X7-uP</bold> towards the P2X family. We performed <bold>X7-uP</bold> labeling in HEK293T cells transiently transfected with various fluorescently tagged rat P2X subunits (P2X1 to P2X7). The biotinylated cells were then visualized using Strept-A 647 labeling through confocal microscopy. These P2X subtypes are closely related to P2X7 but are not expected to exhibit the AZ10606120 allosteric site.</p><p>As expected, confocal microscopy revealed a strong Alexa 647 fluorescence signal in the periphery of cells expressing only P2X7 tagged with the monomeric Scarlet (mScarlet) fluorescent protein (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In contrast, no Alexa 647 signal was detected in cells transiently transfected with other P2X subunits tagged with GFP, although a strong GFP signal was observed for all constructs, confirming correct expression (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Using a commercial cell-surface protein labeling assay, we further confirmed that tagged P2X subunits were expressed at the cell surface—except P2X6, as expected—supporting proper membrane trafficking (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Additionally, co-incubation with AZ10606120 (10 µM) or A740003 (10 µM) during <bold>X7-uP</bold> labeling abolished the Alexa 647 signal but did not affect mScarlet signal, further confirming the specificity of P2X7 labeling (<xref ref-type="fig" rid="fig3">Figure 3A and C</xref>). These data demonstrate the high selectivity of <bold>X7-uP</bold> for P2X7 labeling.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>X7-uP labeling is highly selective for P2X7.</title><p>(<bold>A–B</bold>) Confocal images of HEK293T cells transiently transfected with either P2X7-mScarlet (<bold>A</bold>) or various P2X subunits tagged with GFP (P2X1-GFP, P2X2-GFP, P2X3-GFP, P2X4-GFP, P2X5-GFP, or P2X6-GFP) (<bold>B</bold>) were labeled with <bold>X7-uP</bold> and revealed using Strept-A 647 (red) in FBS-free DMEM. Labeling was performed in the presence of 10 µM AZ10606120 or 10 µM A740003 (<bold>A</bold>). Nuclei were stained with Hoechst (blue). For clarity, mScarlet and GFP signals are displayed in orange and green, respectively. Scale bars, 10 µm. (<bold>C</bold>) Quantification of Alexa 647 fluorescence. Bars represent mean ± standard deviation (s.d.) (n=75–129 cells, <italic>t</italic>-test comparisons to P2X7-mScarlet, ****p&lt;0.0001).</p><p><supplementary-material id="fig3scode1"><label>Figure 3—source code 1.</label><caption><title>RStudio code to generate the histogram of <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig3-code1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data set used to generate <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cell-surface labeling assay of HEK293T cells transfected with various GFP-tagged P2X subunits.</title><p>(<bold>A</bold>) Western blot analysis of cell-surface expression of GFP-tagged P2X subunits. After transient transfection, cells were treated with the cell-impermeant reagent sNHS-SS-biotin. Following extensive washing, cells were lysed, and biotinylated proteins were pulled down and separated on SDS-PAGE. Western blot was revealed using an anti-GFP antibody (@GFP). Molecular mass markers are shown on the right. NT: non-transfected cells (<bold>B</bold>) Corresponding input control for the blot shown in panel A. (<bold>C</bold>) Quantification of cell-surface P2X expression. (<bold>D</bold>) Quantification of total P2X expression. Band intensities of P2X-GFP monomers were normalized to their respective β-actin controls. Mean ± s.e.m., n=5 independent transfections.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots used for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Original image files of western blots used for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig3-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>dSTORM images of HEK293T cells transfected with P2X7-mScarlet.</title><p>(<bold>A-C</bold>) Wild-field fluorescence images (left) and corresponding dSTORM super-resolution images (right) of HEK293T cells labeled with <bold>X7-uP</bold> and revealed with Strept-A 647. Images were acquired either in the absence (<bold>A</bold>) or presence (<bold>B</bold>) of 10 µM AZ10606120. (<bold>C</bold>) Control condition in the absence of <bold>X7-uP</bold>. Scale bars, 5 μm. Scale bars in insets, 0.5 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To further validate our method for single-molecule localization microscopy, we employed dSTORM to visualize the fluorescence emission of individual Alexa 647 fluorophores bound to P2X7 expressed on the plasma membrane of HEK293T cells. Our results confirmed the expression of P2X7 at the cell surface, consistent with confocal microscopy data (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Importantly, no emission was detected when labeling was conducted in the presence of AZ10606120 (10 µM), or when Strept-A 647 was added to cells not treated with <bold>X7-uP</bold> (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref> and C), indicating that the observed emission in dSTORM specifically originated from P2X7.</p></sec><sec id="s2-4"><title>X7-uP labels K82 and K117 in rP2X7</title><p>We next identified the labeling site of <bold>X7-uP</bold>. Since it has been shown that the NASA reagent preferentially reacts with the ε-amino group of lysine side chains (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>), we individually mutated K82, K110, K117, and K300 into alanine, an amino acid residue that cannot react with NASA, in the P2X7-mScarlet background. These residues were selected based on the predicted proximity of their equivalent positions in pdP2X7 to the electrophilic NASA group of <bold>1</bold> in pdP2X7 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We expressed these mutants individually in HEK293T cells and monitored <bold>X7-uP</bold> labeling by quantifying Alexa 647 signals through confocal microscopy. While K110A and K300A mutants did not affect <bold>X7-uP</bold> labeling, where Alexa 647 fluorescence quantification showed comparable levels to that of P2X7-mScarlet (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), a significant reduction in Alexa 647 fluorescence was observed for K82A (79.6 ± 1.0 %, n=154 cells, p&lt;0.0001, <italic>t</italic>-test to the respective control P2X7-mScarlet) and K117A (61.5 ± 2.1%, n=155 cells, p&lt;0.0001). Importantly, a strong mScarlet signal was detected for all mutants, indicating successful expression of mutants in cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Alexa 647 fluorescence reduction at K82A was significantly different from that at K117A (p&lt;0.0001, <italic>t</italic>-test), suggesting a larger contribution of K82 to <bold>X7-uP</bold> labeling. The double mutant K82A/K117A further reduced the signal by 87.3 ± 0.4% (n=199 cells, p&lt;0.0001, <italic>t</italic>-test to respective control P2X7-mScarlet, K82A, or K117A), without affecting P2X7 expression (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). To exclude the possibility that introduced mutations affected <bold>X7-uP</bold> binding, we further demonstrated that the double K82A/K117A mutant did not affect the ability of <bold>X7-uP</bold> to inhibit BzATP-evoked currents (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). These data support the hypothesis that both K82 and K117 are the sites of <bold>X7-uP</bold> labeling in rP2X7.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>X7-uP labels K82 and K117 in rat P2X7.</title><p>(<bold>A</bold>) Molecular docking of <bold>1</bold> (same pose as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>) in pdP2X7, showing distances (in Å) between the reactive carbonyl of <bold>1</bold> (stick representation) and selected α-carbons of nearby residues (blue). Residues shown in parentheses correspond to equivalent rP2X7 residues. (<bold>B</bold>) Confocal images of HEK293T cells transiently transfected with different P2X7 constructs: P2X7-mScarlet, K82A, K117A, and K82A/K117A. Refer to the legend of <xref ref-type="fig" rid="fig3">Figure 3</xref> for additional details. Scale bars, 10 µm. (<bold>C</bold>) Quantification of Alexa 647 fluorescence. Bars represent mean ± s.d. (n=90–190 cells, <italic>t</italic>-test comparisons to indicated conditions, ****p&lt;0.0001). (<bold>D</bold>) Whole-cell currents evoked by 10 µM BzATP are reversibly inhibited by co-application of 0.5 µM <bold>X7-uP</bold> (upper trace) to BzATP in a cell transiently transfected with the double mutant K82A/K117A. The control (absence of <bold>X7-uP</bold>) is shown in the bottom trace. (<bold>E</bold>) Summary of whole-cell inhibition for K82A/K117A (n=7 cells for <bold>X7-uP</bold> and 5 cells for control). Bars represent mean ± s.e.m.; Mann-Whitney test (**p&lt;0.005).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data set and numerical values used to generate <xref ref-type="fig" rid="fig4">Figure 4C and E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Additional data related to <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title><p><xref ref-type="fig" rid="fig4">Figure 4B</xref>. Confocal images of HEK293T cells transiently transfected with different P2X7 constructs (P2X7-mScarlet, K110A, and K300A). Refer to the legend of <xref ref-type="fig" rid="fig3">Figure 3</xref> for additional details. Scale bars, 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>X7-uP reveals uniform membrane distribution of P2X7 in quiescent BV2 cells</title><p>Our data demonstrate the high selectivity of <bold>X7-uP</bold> for rP2X7 in HEK293T cells. We next investigated whether its application extends to native P2X7-expressing cells to reveal endogenous P2X7 expression. We chose BV2 cells, a cultured murine microglial cell line in which functional P2X7 expression has been previously documented (<xref ref-type="bibr" rid="bib58">Raouf et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Trang et al., 2020</xref>). In addition, activation of BV2 cells to mimic microglial inflammation can be effectively stimulated in vitro using both LPS and ATP (<xref ref-type="bibr" rid="bib31">Huang et al., 2024</xref>). Although K117 is not conserved in mouse P2X7, the highly conserved K82 should ensure the successful labeling of mouse P2X7 with <bold>X7-uP</bold> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><p>We first confirmed by ELISA assay that, under untreated conditions, BV2 cells are quiescent as they do not release IL-1β (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). We also confirmed P2X7 expression by Western blot and confocal microscopy following 1 µM <bold>X7-uP</bold> labeling for 10 min in FBS-free DMEM (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). As observed for HEK293T cells, a strong and unique band was detected using a P2X7 antibody only in the presence of <bold>X7-uP</bold> in the pulldown Western blot, at the expected apparent molecular mass of monomeric mouse P2X7 (~68 kDa, unglycosylated form; see lanes 3 and 4 in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). This band disappeared upon co-incubation with AZ10606120 or A740003, while controls in the supernatant consistently showed endogenous P2X7 expression in all lanes, though non-specific bands were also observed, presumably due to the limited specificity of commercially available P2X7 antibodies (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Quantitative Western blotting analysis revealed that 80 ± 1% (mean of triplicate ± s.e.m.) of total P2X7 were labeled in BV2 cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> and B). Confocal microscopy revealed a strong Alexa 647 fluorescence signal in the periphery of BV2 cells that was reduced upon co-incubation with AZ10606120 or A740003 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref> and D). Control with Strept-A 647 alone showed an extremely low fluorescence background level (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref> and D), demonstrating high <bold>X7-uP</bold> labeling specificity in BV2 cells.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>dSTORM data revealed nanoscale P2X7 plasma membrane localization in BV2 cells.</title><p>(<bold>A</bold>) Cartoon and experimental timeline of BV2 cell treatments. IL-1β release was assessed in the supernatant (sup), and the same cells were labeled with 1 µM <bold>X7-uP</bold> after extensive washout. (<bold>B</bold>) Quantification of IL-1β release by ELISA following the indicated treatments: LPS (1 μg/mL for 24 hr), ATP (1 mM for 30 min), BzATP (300 μM for 30 min), and MβCD (15 mM for 15 min). Bars represent mean ± s.e.m. (n=12 samples from three independent experiments). Data were compared using Kruskal-Wallis followed by Dunn’s multiple comparisons (*p=0.0208, #p=0.0362, **p=0.0014, ****p&lt;0.0001). (<bold>C</bold>) Normalized quantification of IL-1β release induced by LPS +ATP or LPS +BzATP in the presence of P2X7 inhibitors AZ10606120 or A740003. Bars represent mean ± s.e.m. (n=6 samples from six independent experiments). One-way ANOVA with Dunnett’s multiple comparisons to control condition for ATP data (****p&lt;0.0001). Kruskal-Wallis followed by Dunn’s multiple comparisons to control condition for BzATP data (*p=0.0414, *** p=0.0006). (<bold>D</bold>) Bright-field and dSTORM images of <bold>X7-uP</bold>-labeled BV2 cells revealed with Strept-A 647 corresponding to experiments shown in panel B. Scale bars, 10 μm. Insets: Magnified dSTORM images. Scale bars, 1 μm. (<bold>E</bold>) Quantification of single P2X7 localization density. Bars represent mean ± s.e.m. (each data point represents a cell, n=3 independent experiments). One-way ANOVA with Tukey’s multiple comparisons (*p&lt;0.019, #p&lt;0.0194, @p&lt;0.0477, ***p&lt;0.0002, ###p&lt;0.0008, ****p&lt;0.0001). (<bold>F</bold>) Relative frequency of cluster size. Inset: percentage of clusters larger than 0.025 mm<sup>2</sup>. (<bold>G</bold>) Number of detections per cluster. Bars represent mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons (*p&lt;0.0197, #p&lt;0.0277, @p&lt;0.0389, ****p&lt;0.0001). (<bold>H</bold>) Images showing tessellation analysis of cells treated either with LPS +ATP or left untreated. Inset: magnification. Scale bars, 200 nm. (<bold>I</bold>) Number of fluorophores per cluster. Bars represent mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons (****p&lt;0.0001).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig5">Figure 5B, C, E, F, G and I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>X7-uP-induced P2X7 labeling in BV2 cells.</title><p>(<bold>A</bold>) Western blot analysis of P2X7 labeling in BV2 cells treated with 1 µM <bold>X7-uP</bold> for 10 min in the absence or presence of 10 µM AZ10606120 or 10 µM A740003. After extensive washing, cells were lysed, and biotinylated proteins were pulled down and separated on SDS-PAGE. Western blot was revealed using a mouse anti-P2X7 antibody (@mP2X7). Molecular mass markers are shown on the right. (<bold>B</bold>) Corresponding input control for the blot shown in panel A. β-Actin was used as a loading control. (<bold>C</bold>) Confocal images of BV2 cells labeled with <bold>X7-uP</bold> and visualized with Strept-A 647 in the absence or presence of AZ10606120 or A740003, or in the absence of <bold>X7-uP</bold> (control, Strept-A 647 alone). Alexa 647 signals are shown in red, and nuclei are stained with Hoechst (blue). Scale bars, 10 µm. (<bold>D</bold>) Quantification of Alexa 647 fluorescence. Bars represent mean ± s.d. (n=46–220 cells, <italic>t</italic>-test comparisons to control, ****p&lt;0.0001).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots used for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Original image files of western blots used for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106096-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Data set used to generate <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig5-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>dSTORM analysis of X7-uP-induced P2X7 labeling in BV2 cells.</title><p>(<bold>A</bold>) Bright-field and dSTORM images of BV2 cells labeled with Strept-A 647 in the presence (+X7-uP, 1 µM) or absence (w/o X7-uP) of <bold>X7-uP</bold>. Scale bars, 10 mm. Insets: Magnified dSTORM images. Scale bars, 1 mm. (<bold>B</bold>) Quantification of the number of localizations in control and <bold>X7-uP</bold>-treated cells (n=3 independent experiments). Bars represent mean ± s.e.m. Unpaired <italic>t</italic>-test, ****p&lt;0.0001. (<bold>C</bold>) Bright-field and dSTORM images of BV2 cells labeled with <bold>X7-uP</bold> and revealed with Strept-A 647 in untreated or MβCD-treated cells. (<bold>D</bold>) dSTORM Metamorph pixelized global images of <bold>X7-uP</bold>-labeled BV2 cells, revealed with Strept-A 647, showed clustering in the LPS, LPS +ATP, and LPS +BzATP conditions compared to the untreated control. Scale bars, 5 µm. Insets: Magnified images. Scale bars, 1 µm. (<bold>E</bold>) Number of detections per cluster (same data set as <xref ref-type="fig" rid="fig5">Figure 5G</xref>, shown in log scale). (<bold>F</bold>) Average intensity per cluster. Bars represent mean ± s.e.m. (<bold>G</bold>) Distance to the closest neighbor. Bars represent mean ± s.e.m.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B, F and G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig5-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Blink detection features.</title><p>Detection of single-molecule blinking (localization) in untreated (NT) and LPS +ATP-treated BV2 cells across several regions of interest (ROIs), as a function of acquisition frames. The first 2000 frames correspond to stack 1 (stk1), and the subsequent 2000 frames correspond to stacks 2, 3, and 7 (stk2, stk 3, and stk7). All single blinks originated from isolated detections, except for ROIs 2 and 3 in the LPS +ATP condition, where they arose from clusters.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig5-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Confocal data of X7-uP-induced P2X7 labeling in BV2 cells.</title><p>(<bold>A</bold>) Confocal images of BV2 cells, untreated or treated with the indicated conditions, labeled with <bold>X7-uP</bold> (1 µM) and visualized with Strept-A 647. Alexa 647 signals are shown in red, and nuclei are stained with DAPI (blue). Scale bars, 10 µm. (<bold>B</bold>) Quantification of Alexa 647 fluorescence. Bars represent mean ± s.e.m. (n=76–376 cells) Data were compared using Kruskal-Wallis followed by Dunn’s multiple comparisons (*p=0.0191, **p=0.0099, ##<italic>P</italic>=0.0027, ****p&lt;0.0001).</p><p><supplementary-material id="fig5s4sdata1"><label>Figure 5—figure supplement 4—source data 1.</label><caption><title>Numerical values used to generate <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-106096-fig5-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig5-figsupp4-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-106096-fig5-video1.mp4" id="fig5video1"><label>Figure 5—video 1.</label><caption><title>dSTORM movie of untreated BV2 cells.</title><p>Stack of 2000 frames (from a total of 20,000 acquired frames), acquired at 33 frames per second.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-106096-fig5-video2.mp4" id="fig5video2"><label>Figure 5—video 2.</label><caption><title>dSTORM movie of LPS +ATP-treated BV2 cells.</title><p>Stack of 2000 frames (from a total of 20,000 acquired frames), acquired at 33 frames per second.</p></caption></media></fig-group><p>To assess how BV2 activation affects P2X7 molecular organization, we employed dSTORM to track single fluorophores tagged to endogenous receptors. In this super-resolution technique, each fluorophore blinks several times before becoming silent due to bleaching or reaching a stable dark state. As a result, clusters of detections could result either from multiple blinks of a single receptor or represent the sum of multiple fluorophore emissions from clustered receptors. To quantify nanoscale object properties, we used Metamorph to obtain pixelized global images for global quantification (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D</xref>), and SR-Tesseler, an open-source segmentation framework based on Voronoï tessellation from localized molecule coordinates (<xref ref-type="bibr" rid="bib44">Levet et al., 2015</xref>), to analyze cluster properties (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>).</p><p>In the control untreated condition (quiescent cells), dSTORM revealed punctated images, while no detections occurred without <bold>X7-uP</bold>, further confirming high labeling specificity in BV2 cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A and B</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref> and <xref ref-type="video" rid="fig5video1">Figure 5—video 1</xref>). Detections are organized into clusters of 44 nm in size (median, 25% percentile 18 nm, 75% percentile 80 nm), with on average 70 ± 15 (mean ± s.e.m.) detections per cluster (n=4 cells, <xref ref-type="fig" rid="fig5">Figure 5G</xref>). Distribution analysis suggests that detections of fluorescent streptavidin conjugates are originating from one single receptor. On average, every P2X7 receptor is separated from its neighbor by a mean inter-cluster distance of 292 ± 5 nm (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2G</xref>). These data suggest that P2X7 is homogenously dispersed on the cell surface of quiescent BV2 cells.</p><p>Since P2X7 has been suggested to be associated with lipid rafts (<xref ref-type="bibr" rid="bib23">Garcia-Marcos et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">García-Marcos et al., 2006</xref>; <xref ref-type="bibr" rid="bib3">Barth et al., 2007</xref>; <xref ref-type="bibr" rid="bib4">Barth et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Gonnord et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Weinhold et al., 2010</xref>), we pre-incubated cells with 15 mM methyl-<italic>β</italic>-cyclodextrin (MβCD), a lipid-raft disrupting agent, for 15 min, and labeled P2X7 with <bold>X7-uP</bold> after extensive washout to remove remaining MβCD (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). MβCD treatment had no effect on IL-1β release, the number of detections per cluster, cluster size, or inter-cluster distance (<xref ref-type="fig" rid="fig5">Figure 5B, F and G</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C and G</xref> and G). We interpret these results to suggest that disrupting lipid rafts does not alter P2X7 distribution in quiescent BV2 cells.</p></sec><sec id="s2-6"><title>X7-uP reveals P2X7 clustering and upregulation in activated BV2 cells</title><p>We analyzed changes in cluster properties following BV2 activation by LPS and P2X7 agonists. To reliably correlate P2X7 spatial distribution with the inflammatory response, we labeled the same BV2 cells used for IL-1β release assays with <bold>X7-uP</bold> (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Previous studies have proposed a two-signal, synergistic model for IL-1β release in microglia and other cell types (<xref ref-type="bibr" rid="bib18">Ferrari et al., 1996</xref>; <xref ref-type="bibr" rid="bib57">Perregaux et al., 2000</xref>; <xref ref-type="bibr" rid="bib20">Ferrari et al., 2006</xref>; <xref ref-type="bibr" rid="bib13">Di Virgilio et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Swanson et al., 2019</xref>), where the first signal involves LPS priming, leading to the intracellular accumulation of pro-IL-1β, while the second involves ATP-dependent P2X7 stimulation, promoting caspase-1 activation and the release of mature IL-1β. We confirmed this model by observing robust IL-1β release when BV2 cells were exposed to 1 μg/mL LPS for 24 hr, followed by 1 mM ATP (or 300 μM BzATP) for 30 min (LPS +ATP or LPS +BzATP; <xref ref-type="fig" rid="fig5">Figure 5B</xref>). No IL-1β release was detected when ATP or BzATP was applied alone, while LPS alone induced significant release. However, this release was significantly less than that induced by co-treatments, representing only 35% of the release observed with LPS +ATP and 21% with LPS +BzATP (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), confirming the synergistic effect. Co-incubation with AZ10606120 or A740003 during agonist exposure reduced IL-1β release to levels observed with LPS alone, demonstrating the role of P2X7 in IL-1β release (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>).</p><p>dSTORM images following treatments are shown in <xref ref-type="fig" rid="fig5">Figure 5D</xref>. Global single-molecule labeling on the cell surface was significantly more pronounced in cells treated with LPS +ATP or LPS +BzATP, and to a lesser extent, though not significantly, in those treated with LPS alone compared to untreated control (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>, and <xref ref-type="video" rid="fig5video2">Figure 5—video 2</xref>). Similar results were obtained using confocal microscopy, although the effect of LPS alone was significant (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A and B</xref> and B). Neither ATP nor BzATP application alone affected the number of detections per cluster, cluster size, or inter-cluster distance. At the cluster level, both LPS and LPS +ATP or LPS +BzATP treatments increased the number of detections per cluster (<xref ref-type="fig" rid="fig5">Figure 5E-G</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D-E</xref>), with no change in inter-cluster distance or average intensity per sub-pixel (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2F</xref> and G), indicating no increase in detection density per pixel. On pixelized images, larger clusters (area greater than 0.025 mm<sup>2</sup>, insert <xref ref-type="fig" rid="fig5">Figure 5F</xref>) emerged following LPS treatment, with or without agonists. Tessellation analysis revealed that the number of fluorophores within clusters significantly increased from ~1.5 in untreated cells to 4.1 ± 0.4 for LPS, 4.9 ± 0.5 for LPS +ATP, and 5.2 ± 0.5 for LPS +BzATP (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). These data demonstrate that pro-inflammatory conditions induce P2X7 clustering by upregulating the average number of P2X7 receptors within clusters, increasing it from one to three, and favoring the formation of larger clusters (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The strong P2X7 clustering induced by the combination of LPS and P2X7 agonists mirrors IL-1β secretion.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Nanoscale redistribution of individual P2X7 receptors in microglia under pro-inflammatory conditions at the plasma membrane.</title><p>The cartoon illustrates two distinct clusters of P2X7 receptors (blue), each adorned with one, two, or three fluorescently tagged tetrameric biotin-bound streptavidin (red). In untreated cells, each cluster contains an average of 1.5 fluorophores per P2X7 receptor. Treatment with LPS and ATP promotes P2X7 clustering by increasing the average number of fluorophores per cluster to between 4 and 5, resulting in an increased number of P2X7 receptors per cluster, from one to three. This redistribution synergistically triggers IL-1β release.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We present a rapid and efficient method for the selective labeling of P2X7 in native cells. This approach allowed us to uncover a nanoscale redistribution mechanism of individual endogenous P2X7 receptors on the plasma membrane of activated BV2 microglial cells, leading to the synergistic release of the pro-inflammatory cytokine IL-1β.</p><p>Our strategy employs an affinity-guided approach, through which we developed <bold>X7-uP</bold>, a selective P2X7 biotinylating reagent that covalently attaches a biotin tag to lysine residues on native P2X7. In rat P2X7 (rP2X7), we identified two lysine residues as labeling sites: K82, a highly conserved residue unique to P2X7, and K117, a residue found only in rP2X7. We found that K82 is the primary labeling site in rP2X7, and given that K117 is absent in mouse P2X7, it is likely that K82 is the only labeled site in BV2-expressing P2X7.</p><p>We demonstrate the effectiveness of <bold>X7-uP</bold> in both heterologous and native expression systems. Compared to existing methods, <bold>X7-uP</bold> offers several advantages. First, it enables rapid labeling of P2X7 within 10 min at low <bold>X7-uP</bold> concentrations (1 µM) in a physiological-like buffer (e.g. FBS-free DMEM). This efficiency is likely due to the use of <italic>N</italic>-cyanomethyl NASA chemistry coupled with the high-affinity ligand AZ10606120. Second, <bold>X7-uP</bold> is highly selective for P2X7: no labeling is observed in cells expressing other P2X subtypes or in the presence of P2X7-specific antagonists. This selectivity arises from AZ10606120’s binding to a unique allosteric site on P2X7 (<xref ref-type="bibr" rid="bib43">Karasawa and Kawate, 2017</xref>), making <bold>X7-uP</bold> particularly suitable for detecting P2X7 in native tissues. This level of specificity outperforms that of commercially available P2X7 antibodies, which often suffer from poor specificity and are generally unreliable for detecting endogenous receptors (<xref ref-type="bibr" rid="bib65">Sim et al., 2004</xref>; <xref ref-type="bibr" rid="bib2">Anderson and Nedergaard, 2006</xref>; <xref ref-type="bibr" rid="bib39">Kaczmarek-Hájek et al., 2012</xref>). While recent nanobody-based approaches have improved P2X7 specificity (<xref ref-type="bibr" rid="bib40">Kaczmarek-Hajek et al., 2018</xref>; <xref ref-type="bibr" rid="bib64">Sierra-Marquez et al., 2024</xref>), our approach is mechanistically distinct and complementary to nanobody-based methods. Third, <bold>X7-uP</bold> achieves covalent biotinylation of P2X7 lysine residues via stable amide bond formation, ensuring that the biotin moiety remains permanently attached, an advantage not afforded by reversible binding strategies. Fourth, <bold>X7-uP</bold> provides a versatile platform to deliver various probes to P2X7, including those for pulldown assays and super-resolution imaging. The strong biotin-streptavidin (or neutravidin) interaction ensures specificity and stability, two crucial criteria for biochemical assays and cell imaging.</p><p>Our results not only confirm P2X7 expression in BV2 microglial cells, as previously reported (<xref ref-type="bibr" rid="bib18">Ferrari et al., 1996</xref>; <xref ref-type="bibr" rid="bib11">Choi et al., 2007</xref>; <xref ref-type="bibr" rid="bib58">Raouf et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Monif et al., 2009</xref>; <xref ref-type="bibr" rid="bib45">Lord et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Monif et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Janks et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Kaczmarek-Hajek et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Trang et al., 2020</xref>), but also reveal its nanoscale localization at the cell surface using dSTORM. In quiescent cells, P2X7 is evenly distributed across the plasma membrane, likely as individual receptors with an average nearest-neighbor distance of ~300 nm, indicating the absence of clustering. To test whether P2X7 associates with cholesterol-enriched lipid rafts, we pre-treated cells with MβCD, a cholesterol-depleting agent that perturbs lipid rafts. This treatment did not affect P2X7 distribution, although we have previously shown in HEK293T cells that MβCD increases P2X7 single-channel mean open time without altering unitary conductance (<xref ref-type="bibr" rid="bib15">Dunning et al., 2021</xref>). These findings suggest that in quiescent BV2 microglial cells, perturbing lipid rafts does not alter the uniform distribution of individual P2X7 receptors, which likely reside within cholesterol-enriched nanodomains.</p><p>Upon BV2 activation, we observed significant nanoscale reorganization of P2X7. Both LPS and ATP (or BzATP) trigger P2X7 upregulation and clustering, increasing the overall number of surface receptors and the number of receptors per cluster, from one to three (<xref ref-type="fig" rid="fig6">Figure 6</xref>). By labeling BV2 cells with <bold>X7-uP</bold> shortly after IL-1β release, we were able to correlate the nanoscale distribution of P2X7 with the functional state of BV2 cells, consistent with the two-signal, synergistic model for IL-1β secretion observed in microglia and other cell types (<xref ref-type="bibr" rid="bib18">Ferrari et al., 1996</xref>; <xref ref-type="bibr" rid="bib57">Perregaux et al., 2000</xref>; <xref ref-type="bibr" rid="bib20">Ferrari et al., 2006</xref>; <xref ref-type="bibr" rid="bib13">Di Virgilio et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Swanson et al., 2019</xref>). In this model, LPS priming leads to intracellular accumulation of pro-IL-1β, while ATP stimulation activates P2X7, triggering NLRP3 inflammasome activation and the subsequent release of mature IL-1β.</p><p>What is the mechanism underlying P2X7 upregulation that leads to an overall increase in surface receptors—does it result from the lateral diffusion of previously masked receptors already present at the plasma membrane, or from the insertion of newly synthesized receptors from intracellular pools in response to LPS and ATP? Although our current data do not distinguish between these possibilities, a recent study suggests that the α1 subunit of the Na<sup>+</sup>/K<sup>+</sup>-ATPase (NKAα1) forms a complex with P2X7 in microglia, including BV2 cells, and that LPS +ATP induces NKAα1 internalization (<xref ref-type="bibr" rid="bib31">Huang et al., 2024</xref>). This internalization appears to release P2X7 from NKAα1, allowing P2X7 to exist in its free form. We speculate that the internalization of NKAα1 induced by both LPS and ATP exposes previously masked P2X7 sites, including the allosteric AZ10606120 sites, thus making them accessible for <bold>X7-uP</bold> labeling.</p><p>In sequence, the first priming step induced by LPS triggers P2X7 clustering and tends to increase the number of cell-surface receptors. This modest increase in P2X7 density may explain the lack of functional upregulation in the amplitude of the P2X7 current component observed in BV2 cells following LPS treatment (<xref ref-type="bibr" rid="bib58">Raouf et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Trang et al., 2020</xref>). The second step, triggered by ATP exposure, further elevates surface receptor levels and activates the P2X7-mediated NLRP3 inflammasome, which cleaves pro-IL-1β into its mature form and facilitates its release. Previous evidence suggests that P2X7 and NLRP3 co-localize in mouse microglia (<xref ref-type="bibr" rid="bib21">Franceschini et al., 2015</xref>), indicating that NLRP3 may reside beneath P2X7 clusters. We speculate that the spatial reorganization and clustering of P2X7 during the LPS-induced priming phase occurs at sites of active inflammation, facilitating synergistic IL-1β secretion in response to ATP. Although additional experiments are needed to precisely colocalize P2X7 clusters with sites of active inflammation, this clustering mechanism might represent a finely tuned regulatory process that links PAMP-induced signaling to DAMP-evoked responses.</p><p>What mechanisms underlie P2X7 clustering in response to inflammatory signals? Several models have been proposed to explain membrane protein clustering, including recruitment to structural scaffolds (<xref ref-type="bibr" rid="bib17">Feng and Zhang, 2009</xref>), partitioning into membrane domains enriched in specific chemical components such as lipid rafts (<xref ref-type="bibr" rid="bib66">Simons and Ikonen, 1997</xref>), and self-assembly mechanisms (<xref ref-type="bibr" rid="bib63">Sieber et al., 2007</xref>). These self-assembly mechanisms include an irreversible stochastic model (<xref ref-type="bibr" rid="bib59">Sato et al., 2019</xref>) and a more recent reversible self-oligomerization model which gives rise to higher-order transient structures (HOTS; <xref ref-type="bibr" rid="bib74">Zhang et al., 2025</xref>). Supported by cryogenic optical localization microscopy with very high resolution (~5 nm), the HOTS model has been observed in various membrane proteins, including ion channels and receptors (<xref ref-type="bibr" rid="bib74">Zhang et al., 2025</xref>). Furthermore, HOTS are suggested to be dynamically modulated and to play a functional role in cell signaling, potentially influencing both physiological and pathological processes (<xref ref-type="bibr" rid="bib73">Zhang and MacKinnon, 2025</xref>). While this hypothesis is compelling, our current dSTORM data lack sufficient spatial resolution to confirm whether P2X7 trimers form HOTS via self-oligomerization. Further biophysical and ultra-high-resolution imaging studies are required to test this model in the context of P2X7 clustering.</p><p>In conclusion, <bold>X7-uP</bold> is a powerful tool for visualizing P2X7 localization at the nanoscale on the cell surface of BV2 cells. We anticipate that <bold>X7-uP</bold> will become a valuable molecular probe for investigating P2X7 organization in other native cell types, such as macrophages, and for resolving the ongoing debate about P2X7 expression in neurons (<xref ref-type="bibr" rid="bib33">Illes et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Miras-Portugal et al., 2017</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Chemical synthesis</title><p>All chemicals were purchased from Sigma-Aldrich, Acros Organics, or Alfa Aesar in analytical grade. An Agilent MM-ESI-ACI-SQ MSD 1200 SL spectrometer or an Agilent LC-MS Agilent RRLC 1200SL/ESI QTof 6520 was used for ESI analysis. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded at 400 or 700, and 100 or 175 MHz, respectively, using the following NMR Bruker instruments: a 400 MHz spectrometer equipped with an Avance III console and a BBO H/F z-gradient probe or a 700 MHz spectrometer equipped with a TCI z-gradient cryoprobe and an Avance III-HD console. Coupling constants (<italic>J</italic>) are quoted in hertz (Hz) and chemical shifts (δ) are given in parts per million (ppm) using the residue solvent peaks (CDCl<sub>3</sub>: 7.26 ppm, MeOD: 3.31 ppm, DMSO-d<sub>6</sub>: 2.50 ppm for <sup>1</sup>H NMR and CDCl<sub>3</sub>: 77.16 ppm, MeOD: 49 ppm, DMSO-d<sub>6</sub>: 39.52 ppm for <sup>13</sup>C NMR). The attributions are given in the following manner: chemical shift followed by the multiplicity in parenthesis (s, d, t, q, m, dd, dt, br corresponding respectively to singlet, doublet, triplet, quadruplet, multiplet, doublet of a doublet, doublet of a triplet, broad; number of protons and coupling constant in Hz).</p><p>HPLC analyses were performed on a Waters high-performance chromatography system (1525 pump, 2996 detector) equipped with a Thermo Betabasics 5 micron analytical column (4.6, 250 nm). A gradient solution was applied, progressing from 100% mQ H<sub>2</sub>O acidified with 0.01% TFA to 100% acetonitrile over 30 min, followed by 10 min at 100% acetonitrile. HPLC purifications were carried out on a Waters high-performance chromatography system (600 double body pump, 2996 detector) equipped with a Thermo Betabasics 5 micron semi-preparative column (10, 250 nm), using the same gradient as described above.</p><fig id="C1" position="anchor"><label>Chemical structure 1.</label><caption><title>5-aminoquinolin-2(1H)-one (3).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem1-v1.tif"/></fig><p>To a solution of 5-nitroquinolin-2(1H)-one (<bold>2</bold>) (1 g, 5.26 mmol, 1 eq.) dissolved in N,N-dimethylformamide (DMF, 40 mL), frozen at -196°C, was added dry palladium on activated charcoal (10%) (448 mg, 2.21 mmol, 0.8 eq.). The solution was allowed to warm to room temperature, and dihydrogen was bubbled in the solution for 5 minutes. The reaction was then maintained under dihydrogen atmosphere and stirred for 16 hours. The crude product was then filtered through a celite pad. The pad was further rinsed with DMF (100 mL) and the filtration product was evaporated to yield a grey solid (825 mg, 98 %).</p><p><sup>1</sup>H NMR (400 MHz, MeOD): δ 8.19 (dd, <italic>J</italic>=9.7, 1.0 Hz, 1 H), 7.26 (m, 1 H), 6.63 (dt, <italic>J</italic>=8.1, 1.0 Hz, 1 H), 6.55 (dd, <italic>J</italic>=8.1, 1.0 Hz, 1 H), 6.47 (d, <italic>J</italic>=9.7 Hz, 1 H). See <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> for spectrum.</p><fig id="C2" position="anchor"><label>Chemical structure 2.</label><caption><title>2-(adamantan-1-yl)acetyl chloride (4).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem2-v1.tif"/></fig><p>2-(1-adamantyl)acetic acid (1.1 g, 5.67 mmol, 1 eq.) was placed in an oven-dried flask equipped with a reflux. Thionyl chloride (10 mL) was added, and the solution was heated to reflux under argon atmosphere for 3 hr. The solvent was then evaporated, and the resulting yellow oil was further dried under vacuum. The obtained compound was used immediately in the next step.</p><fig id="C3" position="anchor"><label>Chemical structure 3.</label><caption><title>2-(adamantan-1-yl)-N-(2-oxo-1,2-dihydroquinolin-5-yl)acetamide (5).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem3-v1.tif"/></fig><p>To a stirred solution of 5-aminoquinolin-2(1 H)-one (<bold>3</bold>) (825 mg, 5.15 mmol, 1 eq.) in anhydrous tetrahydrofuran (THF) was added freshly distilled triethylamine (1.11 mL, 8.24 mmol, 1.6 eq.). The mixture was cooled to 0 °C and a solution of 2-(-adamantan-1-yl)acetyl chloride (1.2 g, 5.67 mmol, 1.1 eq) (<bold>4</bold>) dissolved in dry THF (5 mL) was added dropwise over the course of 15 min to form a gray solution. The solution was kept at 0 °C for 1 hr and brought to 20 °C for 2 more hours. The solution was then evaporated and the obtained solid was rinsed three times with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The solid was further dried to yield the expected compound as a gray solid (1.4 g, 81 %). The product was then used without further purification.</p><p><sup>1</sup>H NMR (400 MHz, MeOD): δ 8.06 (dd, <italic>J</italic>=9.8, 0.8 Hz, 1 H), 7.58–7.54 (m, 1 H), 7.33 (dd, <italic>J</italic>=7.8, 1.1 Hz, 1 H), 7.26 (m, 1 H), 6.65 (d, <italic>J</italic>=9.8 Hz, 1 H), 2.26 (s, 2 H), 2.03 (m, 3 H), 1.86–1.70 (m, 12 H). See <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref> for spectrum.</p><fig id="C4" position="anchor"><label>Chemical structure 4.</label><caption><title>2-(adamantan-1-yl)-N-(2-chloroquinolin-5-yl)acetamide (6).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem4-v1.tif"/></fig><p>To a stirred solution of 2-(adamantan-1-yl)-<italic>N</italic>-(2-oxo-1,2-dihydroquinolin-5-yl)acetamide (<bold>5</bold>) (725 mg, 2.15 mmol, 1 eq.) dissolved in 1,2-dichloroethane (10 mL) was added freshly distilled POCl<sub>3</sub> (618 µL, 6.45 mmol, 3 eq.). The solution was brought to reflux for 16 hr, and the solvent was evaporated. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, filtrated, and evaporated to yield the expected compound as an orange solid (760 mg, 99 %).</p><p><sup>1</sup>H NMR (400 MHz, MeOD): δ 8.43 (dd, <italic>J</italic>=8.8, 0.8 Hz, 1 H), 7.87–7.79 (m, 2 H), 7.72 (dd, <italic>J</italic>=7.2, 1.5 Hz, 1 H), 7.59–7.55 (m, 1 H), 2.30 (s, 2 H), 2.03 (m, 3 H), 1.86–1.72 (m, 12 H). See <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref> for spectrum.</p><fig id="C5" position="anchor"><label>Chemical structure 5.</label><caption><title>2-(adamantan-1-yl)-N-(2-((2-aminoethyl)amino)quinolin-5-yl)acetamide (7).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem5-v1.tif"/></fig><p>To a stirred solution of 2-(adamantan-1-yl)-N-(2-chloroquinolin-5-yl)acetamide (<bold>6</bold>) (488 mg, 1.36 mmol, 1 eq.) in freshly distilled ethanol (10 mL) was added dry K<sub>2</sub>CO<sub>3</sub> (376 mg, 2.72 mmol, 2 eq.) and anhydrous ethylene diamine (4.5 mL, 68 mmol, 50 eq.). The mixture was stirred at reflux for 48 hours. The solution was evaporated and subsequently extracted with 3 × 50 mL CH<sub>2</sub>Cl<sub>2</sub>. Organic layers were combined, washed with 25 mL of brine, and dried over MgSO<sub>4</sub>, filtered, and evaporated. The crude extract was dissolved in a minimum of CH<sub>2</sub>Cl<sub>2</sub> and diethyl ether was added dropwise until the apparition of opalescence. Heptane was then slowly added to precipitate the pure product (262 mg, 51 %) as a yellow solid.</p><p><sup>1</sup>H NMR (400 MHz, MeOD): δ 7.96 (d, <italic>J</italic>=9.2 Hz, 1 H), 7.56–7.46 (m, 2 H), 7.23 (dd, <italic>J</italic>=7.2, 1.4 Hz, 1 H), 6.80 (d, <italic>J</italic>=9.2 Hz, 1 H), 3.57 (t, <italic>J</italic>=6.2 Hz, 2 H), 2.91 (t, <italic>J</italic>=6.2 Hz, 2 H), 2.25 (s, 2 H), 2.03 (m, 3 H), 1.87–1.68 (m, 12 H). See <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref> for spectrum.</p><fig id="C6" position="anchor"><label>Chemical structure 6.</label><caption><title>N-(2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)–4-sulfamoylbenzamide (8).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem6-v1.tif"/></fig><p>To a stirred solution of 2-(adamantan-1-yl)-N-(2-((2-aminoethyl)amino)quinolin-5-yl)acetamide (<bold>7</bold>) (105 mg, 0.28 mmol, 1 eq.) in dry DMF (2.5 mL) were added 4-sulfamoylbenzoic acid (67 mg, 0.33 mmol, 1.2 eq.), 1-Hydroxybenzotriazole (45 mg, 0.33 mmol, 1.2 eq.) and DIEA (129 µL, 0.75 mmol, 2.7 eq.). The solution was cooled to 0 °C and EDC (64 mg, 0.33 mmol, 1.2 eq.) was added. The mixture was then slowly warmed to 20 °C and stirred at 20 °C for 18 hr. The solvent was evaporated and the crude product was purified by invert phase flash chromatography (gradient acetonitrile: H<sub>2</sub>O (0.1% TFA), 0:1 to 1:0 over 30 min, retention time: 16.2 min) to yield pure compounds as an orange solid (100 mg, 64 %).</p><p><sup>1</sup>H NMR (400 MHz, MeOD): δ 8.19 (d, <italic>J</italic>=9.5 Hz, 1 H), 8.02–7.91 (m, 4 H), 7.70 (m, 2 H), 7.45 (dd, <italic>J</italic>=7.5, 1.3 Hz, 1 H), 7.04 (d, <italic>J</italic>=9.5 Hz, 1 H), 3.83 (t, <italic>J</italic>=6.2 Hz, 2 H), 3.73 (t, <italic>J</italic>=6.2 Hz, 2 H), 2.28 (s, 2 H), 2.02 (s, 3 H), 1.88–1.68 (m, 12 H).</p><p><sup>13</sup>C NMR (100 MHz, MeOD): δ 173.92, 169.94, 165.28, 160.81, 156.37, 148.36, 138.62, 136.24, 133.03, 129.52, 127.77, 122.82, 119.63, 119.19, 114.59, 65.67, 55.16, 52.36, 44.52, 38.31, 34.83, 30.50. See <xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref> for spectra.</p><p>MS (ESI): m/z [M<sup>+</sup>] calculated for C<sub>30</sub>H<sub>36</sub>N<sub>5</sub>O<sub>4</sub>S<sup>+</sup>: 562.2483, found 562.2516.</p><fig id="C7" position="anchor"><label>Chemical structure 7.</label><caption><title>tert-butyl (15-((4-((2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)carbamoyl)phenyl)sulfonamido)–15-oxo-3,6,9,12-tetraoxapentadecyl)carbamate (10).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem7-v1.tif"/></fig><p>To a stirred solution of <italic>N</italic>-(2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)–4-sulfamoylbenzamide (<bold>8</bold>) (43 mg, 76 µmol, 1 eq.) in dry DMF (1 mL) were added COOH-OEG4-Boc (<bold>9</bold>) (33.6 mg, 92 µmol, 1.2 eq.), DIEA (33 µL, 191 µmol, 2.5 eq.) and DMAP (2 mg, 15 µmol, 0.2 eq.). The solution was cooled to 0 °C, and EDC (17.6 mg, 92 µmol, 1.2 eq.) was added. The reaction mixture was then slowly warmed to 20 °C and stirred at 20 °C for 16 hr. Every 24 hr over a total of 72 hr, an additional solution of 1 eq. of carboxylic acid, 1 eq. of EDC, and 2 eq. of DIEA prepared at 0 °C in dry DMF (1 mL) was added. The solvent was then evaporated, and 50 mL of a 1:1 CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O solution was added. The organic layer was extracted with 2 × 20 mL of CH<sub>2</sub>Cl<sub>2</sub>. Organic layers were then combined, dried over MgSO<sub>4</sub>, filtered, and evaporated. The crude product was purified by HPLC purification (acetonitrile:H<sub>2</sub>O (0.1% TFA), 0:1 to 1:0 over 30 minutes, retention time: 17.7 min). Pure fractions were combined, extracted with 3 × 20 mL of CH<sub>2</sub>Cl<sub>2</sub>, dried over MgSO<sub>4</sub>, and evaporated to yield pure compound as a dark orange oil (57 mg, 82%).</p><p><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.20 (m, 1 H), 8.01 (m, 4 H), 7.42 (m, 3 H), 6.85 (s, 1 H), 3.79 (m, 2 H), 3.60 (m, 18 H), 3.26 (s, 2 H), 2.48 (s, 2 H), 2.22 (s, 2 H), 1.98 (s, 3 H), 1.77–1.59 (m, 12 H), 1.41 (s, 9 H).</p><p><sup>13</sup>C NMR (100 MHz, CDCl3): δ 171.08, 170.38, 168.12, 166.33, 156.37, 153.55, 139.80, 137.58, 134.55, 133.23, 128.28, 127.87, 121.02, 115.21, 113.45, 108.43, 79.43, 70.45, 70.38, 70.22, 70.13, 66.13, 53.42, 51.57, 42.68, 36.69, 33.47, 28.51. See <xref ref-type="fig" rid="fig1s8">Figure 1—figure supplement 8</xref> for spectra.</p><fig id="C8" position="anchor"><label>Chemical structure 8.</label><caption><title>N-(2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)–4-(N-(17-oxo-21-((3aR,4R,6aS)–2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)–4,7,10,13-tetraoxa-16-azahenicosanoyl)sulfamoyl)benzamide (11).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem8-v1.tif"/></fig><p>To a stirred solution tert-butyl (15-((4-((2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)carbamoyl)phenyl)sulfonamido)–15-oxo-3,6,9,12-tetraoxapentadecyl)carbamate (<bold>10</bold>) (7.6 mg, 8 µmol, 1 eq.) in 700 µl of CH<sub>2</sub>Cl<sub>2</sub> was added 100 µl of TFA and the solution was left under Argon for 1 hr at 20 °C. After completing deprotection of the amine (confirmed by HPLC), the solvent was evaporated and the residue was further dried by three successive co-evaporation with anhydrous toluene (5 mL). Anhydrous DMF was then added to the flask (1 mL), followed by N-methylmorpholine (2 µL, 17 µmol, 2 eq.), biotin (3 mg, 13 µmol, 1.5 eq.), and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)–4-methyl-morpholinium chloride (DMTMM, 3.4 mg, 13 µmol, 1.5 eq.). The solution was left 2 hr at 20 °C. The solvent was then evaporated and the pure product was obtained by HPLC purification (acetonitrile: H<sub>2</sub>O (0.1% TFA), 0:1 to 1:0 over 30 min, retention time: 18.1 min) to yield an orange solid (7 mg, 80%).</p><p><sup>1</sup>H NMR (500 MHz, MeOD): δ 10.01 (s, 1 H), 9.01 (br, 1 H), 8.29 (s, 1 H), 8.07–7.96 (m, 4 H), 7.82 (t, J=5.6 Hz, 1 H), 7.76–7.69 (br, 1 H), 7.60 (br, 1 H), 7.09 (s, 1 H), 6.41 (s, 1 H), 6.36 (s, 1 H), 4.31 (dd, J=7.6, 4.2 Hz, 1 H), 4.13 (dd, J=7.6, 4.4 Hz, 1 H), 3.76 (br, 2 H), 3.64 (br, 2 H), 3.55–3.35 (m, 16 H), 3.18 (q, J=6.2 Hz, 2 H), 3.12–3.07 (m, 1 H), 2.82 (dd, J=12.6, 5.3 Hz, 1 H), 2.58 (J=12.6, 2 H), 2.21 (m, 2 H), 2.06 (t, J=7.3 Hz, 2 H), 1.97 (s, 3 H) 1.72–1.57 (m, 12 H), 1.53–1.41 (m, 3 H), 1.35–1.23 (m, 3 H).</p><p><sup>13</sup>C NMR (100 MHz, MeOD): δ 174.74, 172.09, 170.58, 168.23, 164.72, 159.59, 153.15, 137.88, 136.88, 135.05, 132.40, 128.07, 127.70, 122.07, 116.79, 115.21, 113.51, 70.14, 70.12, 70.00, 69.17, 65.80, 61.98, 60.26, 55.58, 50.55, 42.46, 39.67, 38.97, 36.48, 35.33, 33.05, 28.79, 28.33, 28.09, 25.44. See <xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9</xref> for spectra.</p><fig id="C9" position="anchor"><label>Chemical structure 9.</label><caption><title>N-(2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2- yl)amino)ethyl)–4-(N-(cyanomethyl)-N-(17-oxo-21-((3aR,4R,6aS)–2-oxo- hexahydro-1H-thieno[3,4-d]imidazol-4-yl)–4,7,10,13-tetraoxa-16-azahenico- sanoyl)sulfamoyl)benzamide (X7-uP).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-chem9-v1.tif"/></fig><p>To a stirred solution of N-(2-((5-(2-(adamantan-1-yl)acetamido)quinolin-2-yl)amino)ethyl)–4-(N-(17-oxo-21-((3aR,4R,6aS)–2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)–4,7,10,13-tetraoxa-16-azahenicosanoyl)sulfamoyl)benzamide (<bold>11</bold>) (4 mg, 4 µmol, 1 eq.), previously dried with five successive co-evaporation with anhydrous toluene (5 mL), in dried DMF (0.5 mL) were added freshly distilled DIEA (32 µl, 190 µmol, 50 eq.) and iodoacetonitrile (13 µl, 190 µmol, 50 eq.). The iodoacetonitrile was dried over an alumina plug prior to use. The solution was stirred for 16 hr at 20 °C in the dark, and the solvent was then evaporated. The crude product was purified by HPLC (acetonitrile: H<sub>2</sub>O (0.1% TFA), 0:1 to 1:0 over 30 min, retention time: 19.1 min), affording the pure compound as a brown solid (3.3 mg, 80 %).</p><p><sup>1</sup>H NMR (700 MHz, DMSO): δ 10.02 (s, 1 H), 9.08 (br, 1 H), 8.29 (s, 1 H), 8.14 (d, <italic>J</italic>=8.3 Hz, 2 H), 8.08 (d, <italic>J</italic>=8.3 Hz, 2 H), 7.83 (t, <italic>J</italic>=5.6 Hz, 1 H), 7.76–7.72 (br, 1 H), 7.60 (br, 1 H), 7.09 (s, 1 H), 6.42 (s, 1 H), 6.37 (s, 1 H), 5.02 (s, 2 H), 4.31 (dd, <italic>J</italic>=7.8, 5.0 Hz, 1 H), 4.13 (dd, <italic>J</italic>=7.7, 4.4 Hz, 1 H), 3.77 (s, 2 H), 3.66 (s, 2 H), 3.60 (t, <italic>J</italic>=6.1 Hz, 2 H), 3.53–3.42 (m, 12 H), 3.39 (t, <italic>J</italic>=6.0 Hz, 2 H), 3.18 (q, <italic>J</italic>=6.0 Hz, 2 H), 3.12–3.07 (m, 1 H), 2.94 (t, <italic>J</italic>=6.1 Hz, 2 H), 2.82 (dd, <italic>J</italic>=12.6, 5.1 Hz, 1 H), 2.58 (d, <italic>J</italic>=12.6 Hz, 2 H), 2.22 (m, 2 H), 2.07 (t, <italic>J</italic>=7.4 Hz, 2 H), 1.97 (s, 3 H), 1.73–1.58 (m, 12 H), 1.53–1.43 (m, 4 H), 1.34–1.23 (m, 2 H).</p><p><sup>13</sup>C NMR (175 MHz, DMSO): δ 170.91, 169.04, 168.67, 164.13, 161.47, 161.06, 156.95, 156.77, 138.73, 137.84, 133.90, 129.02, 128.80, 127.17, 126.67, 116.81, 116.40, 114.96, 114.70, 68.52, 68.47, 68.44, 68.42, 68.31, 68.27, 63.96, 59.78, 57.94, 54.15, 53.63, 48.88, 40.83, 38.72, 37.15, 35.13, 34.63, 34.52, 33.82, 32.69, 31.52, 29.50, 29.42, 26.92, 26.78, 26.76, 23.99. See <xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref> for spectra.</p><p>MS (ESI): m/z [M+] calculated for C<sub>53</sub>H<sub>71</sub>N<sub>9</sub>O<sub>11</sub>S<sub>2</sub><sup>+</sup>: 1074.4787, found 1074.4797.</p></sec><sec id="s4-2"><title>Molecular modeling</title><p>The P2X7 structure resolved with the allosteric inhibitor AZ10606120 was retrieved from the Protein Data Bank (PDB, code 5U1W, <xref ref-type="bibr" rid="bib42">Karasawa and Kawate, 2016</xref>). The inhibitor was removed, and docking simulations were performed using AutoDock Vina 1.5.6. A 30 Å box centered on the quinoline core of AZ10606120 was used for docking, set before ligand removal. The cartoon shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> was created using tetrameric biotin-bound streptavidin (PDB code 1MK5, <xref ref-type="bibr" rid="bib32">Hyre et al., 2006</xref>) and rP2X7 (PDB code 6U9W, <xref ref-type="bibr" rid="bib48">McCarthy et al., 2019</xref>). Tetrameric biotin-bound streptavidin was positioned relative to K82, using the maximum 18.5 Å distance between the α-carbon of K82 and the carboxylate carbon of the bound biotin.</p></sec><sec id="s4-3"><title>Cell culture and transfection</title><p>HEK293T cells (ATCC CRL-3216; authenticated by STR profiling) and mouse BV2 microglia cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0182">CVCL_0182</ext-link> from Banca-Biologica e Cell Factory N° ATL03001, a kind gift from Dr. R. Schlichter, Institute of Cellular and Integrative Neuroscience, University of Strasbourg, France; authenticated by STR profiling) were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM 31966–021) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin (Gibco Life Technologies, USA). Cells were grown at 37 °C in a humidified cell incubator with 5% CO<sub>2</sub>. Both cell lines tested negative for mycoplasma contamination.</p><p>For transfection, cells were grown to 70–80% confluence, and the calcium phosphate precipitation method was employed. The cDNA encoding rat P2X7-mScarlet (<xref ref-type="bibr" rid="bib7">Bindels et al., 2017</xref>), P2X1-GFP, P2X2-GFP, P2X3-GFP, P2X4-GFP, P2X5-GFP, or P2X6-GFP (all kind gifts from Dr. F. Rassendren, Institut de Génomique Fonctionelle, University of Montpellier, France) was contained within pcDNA3.1(+) plasmids (Invitrogen, USA). rP2X7c-myc was obtained as previously described (<xref ref-type="bibr" rid="bib15">Dunning et al., 2021</xref>). 24 hr after transfection, the medium was replaced with fresh medium. For whole-cell patch-clamp experiments, cells were co-transfected with the rP2X7 construct (0.8 µg) and an eGFP (0.3 µg) which allowed to identify cells that had undergone efficient transfection. For biochemical experiments, each 100 mm dish was transfected with P2X7c-myc construct (10 µg). For confocal imaging and dSTORM experiments, HEK293T cells were transfected with 1 µg of the indicated construct.</p></sec><sec id="s4-4"><title>Mutagenesis</title><p>Site-directed mutations were introduced into the P2X7-mScarlet cDNA in the pcDNA3.1(+) using KAPA HiFi HotStart PCR kit (Cliniscience, France) as previously described (<xref ref-type="bibr" rid="bib28">Habermacher et al., 2016</xref>). All mutations were confirmed by DNA sequencing.</p></sec><sec id="s4-5"><title>Electrophysiology patch-clamp</title><p>Electrophysiological recordings in whole-cell configuration were carried out as previously described (<xref ref-type="bibr" rid="bib15">Dunning et al., 2021</xref>). Briefly, patch pipettes were pulled from borosilicate glass capillaries and microforged to yield a resistance of 3–5 MΩ. Cells were voltage-clamped to –60 mV using EPC10 USB amplifier (HEKA, Reutlingen, Germany), and data were recorded with PATCHMASTER software (version V2X90.5). Ligands were applied via a perfusion system, using three capillary tubes placed directly over the cell of interest.</p><p>2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate (BzATP) (triethylammonium salt, Alomone labs, Israel) was used as P2X7 agonist at a concentration of 10 µM. AZ10606120 and <bold>X7-uP</bold> were used at the indicated concentrations. BzATP was dissolved in Normal Extracellular Solution (NES), containing 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl<sub>2</sub>, 0.1 mM MgCl<sub>2</sub>, 10 mM HEPES, and 10 mM glucose, with a pH of 7.32–7.33. AZ10606120 and <bold>X7-uP</bold> were prepared as concentrated stocks in DMSO and diluted in NES to the desired working concentration (&lt;0.1% DMSO). Only one cell was patched per coverslip.</p></sec><sec id="s4-6"><title>Labeling reaction with X7-uP</title><p><bold>X7-uP</bold> was stored as a DMSO stock solution (24.9 mM) and diluted in FBS-free DMEM to achieve the desired working concentration for labeling (&lt;0.1% DMSO). After three washing steps with freshly prepared sterile-filtered PBS+ buffer (containing 137 mM NaCl, 2.68 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.76 mM KH<sub>2</sub>PO<sub>4</sub>, 1 mM MgCl<sub>2</sub> and 0.4 mM CaCl<sub>2</sub>), cells were incubated with <bold>X7-uP</bold> diluted in FBS-free DMEM for the indicated time at 37 °C. Following incubation, cells were washed three times with PBS+ buffer and treated as indicated. For confocal and dSTORM experiments, biotinylated cells were incubated with 1 µg/mL of Strept-A 647 (S21374, Invitrogen, USA) for 10 min in PBS+ buffer containing 1% bovine serum albumin (BSA) at 37 °C. After three additional washes with PBS+ buffer, cells were fixed as described below.</p></sec><sec id="s4-7"><title>Cell-surface protein biotinylation assay</title><p>Cell-surface biotinylation assay was performed 24 hr after transfection of HEK239T cells with different GFP-labeled P2X subtypes. Cells were washed three times in ice-cold PBS+ buffer (pH 8.0) and incubated in 2 mM sNHS-SS-Biotin in ice-cold PBS+ for 30 min under gentle agitation. The reaction was quenched with 20 mM Tris in PBS+ for 10 min. After three additional washes, cells were lysed for 90 min at 4 °C under thorough agitation in lysis buffer (20 mM HEPES, 100 mM NaCl, 5 mM EDTA, 1 % Triton-X-100, protease inhibitor tablets). Lysates were centrifuged at 10,000 rpm for 10 min at 4 °C, and the supernatant (input fraction) was collected. The cleared lysates were then incubated overnight at 4 °C with NeutrAvidin-agarose resin (Thermo Fisher) pre-washed with lysis buffer. The resin was subsequently washed three times with washing buffer (20 mM HEPES, 500 mM NaCl, 5 mM EDTA, 1% Triton-X-100, protease inhibitor tablets) and twice with lysis buffer. Bound proteins were resuspended in NuPAGE LDS sample buffer (Thermo Fisher) containing 70 mM DTT, boiled for 10 min, and separated on a NuPAGE Novex 4–12% Bis-Tris gel (Thermo Fisher, USA) in MOPS buffer. Transfer and western blotting were carried out as described below.</p></sec><sec id="s4-8"><title>Pull down, SDS-PAGE, and western blot</title><p>Cells were solubilized by vortexing in a lysis buffer (20 mM HEPES, 100 mM NaCl, 1% Triton-X-100, 5 mM EDTA, 1% protease inhibitor (Thermo Fisher, Waltham, MA, USA)) at 4 °C for 90 min. Following centrifugation (10,000 rpm, 10 min), supernatants were collected, mixed with the NuPAGE LDS loading buffer (Thermo Fisher) containing 70 mM dithiothreitol (DTT), boiled for 10 min, and run on a NuPAGE Novex Bis-Tris 4–12% (Thermo Fisher, USA) in MOPS buffer. Proteins were transferred to a nitrocellulose membrane using semi-wet transfer (TransBlot Turbo system, Bio-Rad, CA, USA), and the membrane was blocked for 30 min in TPBS buffer (PBS buffer supplemented with 1% milk powder, 0.5% BSA, and 0.05% Tween-20). The membrane was then incubated overnight at 4 °C under gentle agitation with primary antibodies: 1:2000 anti-GFP antibody (MA5-15256, Thermo Fisher), 1:500 anti-c-Myc mouse antibody (13–2500, Invitrogen, Thermo Fisher), 1:500 rabbit anti-P2X7 antibody (APR-008, Alomone Labs, Israel), or mouse 1:5000 anti-β-actin (A5441, Sigma Aldrich). Proteins were visualized using 1:10,000 horseradish peroxidase-conjugated secondary antibodies directed against mouse or rabbit (NA9310, GE Life Sciences and 31460, Invitrogen, respectively) and a chemiluminescent substrate (Amersham ECL Select Western Blotting Detection, GE Life Sciences, MA, USA) on an Imager 600 (Amersham, IL, USA).</p><p>For pull-down experiments, solubilized cells (as described above) were incubated overnight at 4 °C under gentle agitation with Pierce NeutrAvidin agarose resin (29200, Thermo Fisher). Samples preparation and Western blotting was carried out as described above.</p></sec><sec id="s4-9"><title>Coverslip preparation</title><p>For confocal imaging and super-resolution experiments, coverslips (0117580, No. 1.5 H, Marenfield, Germany) were cleaned by incubation in freshly made piranha solution (H<sub>2</sub>SO<sub>4</sub>:H<sub>2</sub>O<sub>2</sub> 50% 3:1) at 60 °C for 30 min. The cleaning solution was replaced with fresh piranha solution, and the coverslips were sonicated for an additional 30 min. After discarding the piranha solution, coverslips were washed 10 times with ultra-pure water and sonicated in ultrapure water (10 × 3 min each) to ensure complete removal of any cleaning residue. Coverslips were then dispatched in 12-well plates and exposed to UV light for 30 min. For HEK293T cells, the coverslips were treated with poly-L-lysine for 1 hr at 37 °C and subsequently washed with ultra-pure water before use. For BV2 cells, no treatment with poly-L-lysine was performed.</p></sec><sec id="s4-10"><title>BV2 microglia stimulation</title><p>BV2 microglia cells were seeded on treated coverslips (as described above) in a 12-well plate containing standard DMEM medium with 10% FBS. After 24 hr, cells were incubated in DMEM medium with 1% FBS for 24 hr, either left untreated or treated with <italic>Escherichia coli</italic> O111:B4 LPS (1 μg/mL, L2630, Sigma Aldrich, USA). After washing once with freshly prepared sterile-filtered PBS+, cells were incubated in PBS+, either in the absence (vehicle) or supplemented with 1 mM adenosine 5′-triphosphate (ATP disodium salt hydrate, A7699, Sigma Aldrich) for 30 min, 300 µM BzATP for 30 min, or 15 mM MβCD (Sigma Aldrich, USA) for 15 min at 37 °C in a humidified cell incubator with 5% CO<sub>2</sub>. After treatments, supernatants were collected for the IL-1β ELISA assay, and cells were labeled with 1 µM <bold>X7-uP</bold> as described above.</p></sec><sec id="s4-11"><title>ELISA assay</title><p>IL-1β levels were measured using the IL-1β Mouse Uncoated ELISA Kit (ref. 88–7013, Invitrogen, USA) following the manufacturer’s protocol. Developed plates were read using a SAFAS Monaco plate reader with SP2000 version 7 software.</p></sec><sec id="s4-12"><title>Cell fixation</title><p>Cells were fixed by 4% paraformaldehyde (PFA) in PBS, pH 8.0 for 20 min at 20 °C. Fixed cells were then washed three times and incubated with fresh PBS buffer for 3 × 5 min, followed by incubation in 100 mM glycine (in PBS buffer) for 15 min at 20 °C. After three washes, cells were stored at 4 °C until use. All washing steps were performed with freshly made, sterile-filtered PBS buffer.</p></sec><sec id="s4-13"><title>Cytochemistry</title><p>For confocal imaging, coverslips containing fixed cells were treated with 4 µg/mL of Hoechst 33342 pentahydrate (bis-benzimide) (H21491, Molecular Probes, Life Technologies, USA) in PBS buffer for 10 min. The staining solution was discarded, and coverslips were washed three times with PBS buffer, rinsed with ultra-pure water, mounted on microscopy slides with the Prolong Gold Antifade (P36930, Invitrogen, USA), and allowed to dry overnight in the dark before use.</p><p>For confocal imaging of BV2 cells shown in <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>, coverslips were rinsed with ultra-pure water, mounted on microscopy slides using the Prolong Diamond Antifade with DAPI (P36962, Invitrogen, USA), and allowed to dry overnight in the dark before use.</p><p>For dSTORM experiments in HEK293T cells, coverslips were incubated at room temperature for 6 min in a PBS solution containing 1:5000 fluorescent microspheres (Tetraspeck, Invitrogen, USA) as fiducial markers for lateral drift correction during image reconstruction, rinsed with ultra-pure water, mounted on microscopy slides on a Vectashield H-1000 (Vector Laboratories, USA) containing a 50 mM TRIS-glycerol (obtained by diluting 5% v/v TRIS pH 8.0 in glycerol and filtered on 0.22 µm filter) in a 1:4 ratio, and sealed using dental cement (Picodent, Germany; <xref ref-type="bibr" rid="bib55">Olivier et al., 2013</xref>).</p><p>For dSTORM experiments in BV2 cells, coverslips were first incubated at room temperature for 6 min in a PBS solution containing 1:5000 fluorescent microspheres (Tetraspeck, Invitrogen, USA). The coverslips were then mounted in a Ludin chamber (Life Imaging Services), where a buffer composed of an oxygen scavenger (glucose oxidase) and a reducing agent (2-mercaptoethylamine) was added (600 μL). The Ludin chamber was sealed with an 18 mm coverslip to prevent oxygen exchange.</p></sec><sec id="s4-14"><title>Confocal imaging</title><p>Confocal imaging was captured with Leica SPE (63 x oil immersion objective, N.A. 1.4). Excitation (λexc) and emission (λem) wavelengths were as follows: DAPI, Hoechst (λexc = 405 nm, λem = 430–480 nm), GFP (λexc = 488 nm, λem = 500–545 nm), mScarlet (λexc = 561 nm, λem = 570–610 nm) and Alexa Fluor-647 (λexc 635 nm, λem = 650–700 nm).</p></sec><sec id="s4-15"><title>dSTORM imaging and reconstruction</title><p>dSTORM acquisitions in HEK293T cells were conducted on a homemade system built on a Nikon Eclipse Ti microscope, equipped with a 100 x oil immersion objective (N.A. 1.49; <xref ref-type="bibr" rid="bib25">Glushonkov et al., 2018</xref>). A 642 nm laser line was used to excite the Alexa Fluor-647 fluorophore, set to a power of 134 mW (resulting in an intensity of 2.7 kW/cm<sup>2</sup>). Samples were imaged with an EM-CCD camera (Hamamatsu, ImagEM) maintained at –60 °C. Z-stabilization was ensured by the Nikon Perfect Focus System integrated into the microscope. Acquisition was performed in TIRF mode controlled using Micro-Manager 1.4.23 (<xref ref-type="bibr" rid="bib16">Edelstein et al., 2014</xref>). Single-molecule localization was achieved by analyzing a stack of 15,000 images with the ThunderSTORM ImageJ plugin (<xref ref-type="bibr" rid="bib56">Ovesný et al., 2014</xref>). The following parameters were used: image filtering – Difference-of-Gaussians filter (sigma 1 = 1.2 px, sigma 2 = 1.9 px), approximate localization of molecules: centroid of connected components (peak intensity threshold std (Wave.F1), sub-pixel localization of molecules: PSF: Integrated Gaussian (fitting radius: 6 px, fitting method: Weighted Least squares, initial sigma: 1.6 px)). Results were filtered by sigma, localization precision, and intensities values: 110 nm&lt; sigma &lt;220 nm, precision &lt;25 nm and intensity &lt;2000.</p><p>dSTORM acquisitions in BV2 cells were performed on a commercial LEICA DMi8 (Leica, Germany) inverted microscope equipped with anti-vibrational table (TMC, USA) to minimize drift, along with a Leica HC PL APO 100 X oil immersion TIRF objective (NA 1.47). For sample excitation, the microscope was equipped with a fiber-coupled laser launch composed of the following wavelengths: 405, 488, 532, 561, and 642 nm (Roper Scientific, Evry, France). Samples were imaged with an EMCCD camera (Teledyne Photometrics). Z stabilization was guaranteed by the Leica auto focus system integrated into the microscope. The 642 nm laser was used at a constant power to excite the Alexa Fluor-647 fluorophore, and the 405 nm laser was adjusted throughout the acquisition to control the level of single molecules per frame. Image acquisition was performed in TIRF mode controlled by MetaMorph software (Molecular Devices), with a 30 ms frame duration and a stack of 20,000 frames per acquisition on a 512 x 512-pixel ROI (pixel size = 160 nm).</p><p>Super-resolved images were reconstructed using the PALMTracer plugin for MetaMorph (<xref ref-type="bibr" rid="bib9">Butler et al., 2022</xref>). The localizations were first extracted using a consistent intensity threshold across the entire dataset. Subsequently, super-resolved images were generated from these localizations with a pixel size of 40 nm. The density of localization was then extracted on each image, based on ROIs determined around the plasma membrane.</p></sec><sec id="s4-16"><title>Cluster size measurement</title><p>Density-based clustering was performed using SR-Tesseler software (<xref ref-type="bibr" rid="bib44">Levet et al., 2015</xref>) with the following input parameters: density factor 1 = 1; density factor 2 = 0.7, max length = 250 nm and min locs = 10; max locs = 200, max distance = 2 µm. The data obtained were further analyzed with GraphPad Prism (version 8.0.2).</p></sec><sec id="s4-17"><title>Kinetic analysis of X7-uP labeling</title><p>The <bold>X7-uP</bold> labeling reaction follows a kinetic model in which a reversible ligand binding reaction (here <bold>X7-uP</bold>) precedes an irreversible chemical reaction, as described previously (<xref ref-type="bibr" rid="bib69">Tamura et al., 2018</xref>). In the presence of a large excess of <bold>X7-uP</bold> relative to P2X7 sites, the pseudo-first-order reaction rate constant (<italic>k</italic><sub>app</sub>) is given by <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>:<disp-formula id="equ1"><label>(1)</label><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle f\left (t\right)={\rm exp}\left (- k_{app}t\right)$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <italic>t</italic> is the labeling reaction time at a given <bold>X7-uP</bold> concentration. The relationship between <italic>k</italic><sub>app</sub> and <bold>X7-uP</bold> concentration is described by <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>:<disp-formula id="equ2"><label>(2)</label><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mtext>X7-uP</mml:mtext><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle k_{app}=\frac{k_{L}}{1+K_{d}/\left [\text{X7-uP}\right ]}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where K<sub>d</sub> is the dissociation constant of <bold>X7-uP</bold> and <italic>k</italic><sub>L</sub> is the rate constant of the irreversible chemical reaction.</p></sec><sec id="s4-18"><title>Data analysis</title><p>All experiments were conducted with at least three independent experiments. Statistical significance was assumed when the <italic>P</italic>-value was &lt;0.05. Graphs were generated using RStudio (version 1.4.1717) and ggplot2 package (version 3.3.5) or GraphPad Prism.</p><p>Western blot quantification was performed using the ImageJ gel analysis tool.</p><p>For confocal data, membrane fluorescence intensities were manually selected using the ROI function of ImageJ (version 2.3.0/1.53 f). Data were then analyzed using in-house written R scripts, employing the following packages: ggplot2, reshape2 (version 1.4.4), readxl (version 1.3.1), dplyr (version 1.0.7), Rmisc (version 1.5), and naniar (version.6.1). For confocal data shown in <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>, membrane intensities were automatically selected. A threshold was first applied to distinguish particles from the background, after which all particles &gt;20 pixels in size were automatically selected and combined for each cell. After manually adjusting the selections, the integrated density (mean gray value x pixel number) was determined using ImageJ’s Measure function. Data were then analyzed with GraphPad.</p><p>For cluster analysis, data extracted from SR-Tesseler (cluster diameter, number of detections per cluster, inter-cluster distance) were computed with GraphPad Prism for each cell.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-106096-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript, figures, figure supplements and source data files. RStudio codes to generate histograms of <xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref> are provided in the source data files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Pr. P Didier for training on dSTORM in HEK293T cells, Dr. F Rassendren for providing P2X7-mScarlet and P2X-GFP constructs, Pr. R Schlichter for providing BV2 cells, and the IINS PBC facility and Dr. M Sainlos for providing mSA. This work was supported by the Agence Nationale de la Recherche (Grant ANR-20-CE14-0016-02), the Ministère de la Recherche (PhD grant to BA), the International Center for Frontier Research in Chemistry (Labex CSC-TGR-18) (PhD grant to FC), and The Région Grand Est (PhD grant to FC). This work also benefited from support provided by the University of Strasbourg Institute for Advanced Study (USIAS) for a fellowship, within the French national program “Investments for the Future” (Idex-Unistra) and from the Interdisciplinary Thematic Institute NeuroStra, as part of the ITI 2021–2028 program of the University of Strasbourg, CNRS and Inserm, supported by EUR (ANR-17-EURE-0022) (PhD grant extension to BA) under the framework of the French Program “Investments for the Future”.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allsopp</surname><given-names>RC</given-names></name><name><surname>Dayl</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>725</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-00732-5</pub-id><pub-id pub-id-type="pmid">28389651</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CM</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons</article-title><source>Trends in Neurosciences</source><volume>29</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2006.03.003</pub-id><pub-id pub-id-type="pmid">16564580</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>K</given-names></name><name><surname>Weinhold</surname><given-names>K</given-names></name><name><surname>Guenther</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>MT</given-names></name><name><surname>Schnittler</surname><given-names>H</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Caveolin-1 influences P2X7 receptor expression and localization in mouse lung alveolar epithelial cells</article-title><source>The FEBS Journal</source><volume>274</volume><fpage>3021</fpage><lpage>3033</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05830.x</pub-id><pub-id pub-id-type="pmid">17498208</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>K</given-names></name><name><surname>Weinhold</surname><given-names>K</given-names></name><name><surname>Guenther</surname><given-names>A</given-names></name><name><surname>Linge</surname><given-names>A</given-names></name><name><surname>Gereke</surname><given-names>M</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Characterization of the molecular interaction between caveolin-1 and the P2X receptors 4 and 7 in E10 mouse lung alveolar epithelial cells</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>40</volume><fpage>2230</fpage><lpage>2239</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2008.03.001</pub-id><pub-id pub-id-type="pmid">18407780</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ao</surname><given-names>H</given-names></name><name><surname>Shoblock</surname><given-names>JR</given-names></name><name><surname>Lord</surname><given-names>B</given-names></name><name><surname>Aluisio</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>I</given-names></name><name><surname>Nepomuceno</surname><given-names>D</given-names></name><name><surname>Neff</surname><given-names>RA</given-names></name><name><surname>Welty</surname><given-names>N</given-names></name><name><surname>Lovenberg</surname><given-names>TW</given-names></name><name><surname>Bonaventure</surname><given-names>P</given-names></name><name><surname>Wickenden</surname><given-names>AD</given-names></name><name><surname>Letavic</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567</article-title><source>British Journal of Pharmacology</source><volume>170</volume><fpage>624</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1111/bph.12314</pub-id><pub-id pub-id-type="pmid">23889535</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Biber</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The microglial ATP-gated ion channel P2X7 as a CNS drug target</article-title><source>Glia</source><volume>64</volume><fpage>1772</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1002/glia.23001</pub-id><pub-id pub-id-type="pmid">27219534</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindels</surname><given-names>DS</given-names></name><name><surname>Haarbosch</surname><given-names>L</given-names></name><name><surname>van Weeren</surname><given-names>L</given-names></name><name><surname>Postma</surname><given-names>M</given-names></name><name><surname>Wiese</surname><given-names>KE</given-names></name><name><surname>Mastop</surname><given-names>M</given-names></name><name><surname>Aumonier</surname><given-names>S</given-names></name><name><surname>Gotthard</surname><given-names>G</given-names></name><name><surname>Royant</surname><given-names>A</given-names></name><name><surname>Hink</surname><given-names>MA</given-names></name><name><surname>Gadella</surname><given-names>TWJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mScarlet: a bright monomeric red fluorescent protein for cellular imaging</article-title><source>Nature Methods</source><volume>14</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4074</pub-id><pub-id pub-id-type="pmid">27869816</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Introduction: P2 receptors</article-title><source>Current Topics in Medicinal Chemistry</source><volume>4</volume><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.2174/1568026043451014</pub-id><pub-id pub-id-type="pmid">15078211</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>C</given-names></name><name><surname>Saraceno</surname><given-names>GE</given-names></name><name><surname>Kechkar</surname><given-names>A</given-names></name><name><surname>Bénac</surname><given-names>N</given-names></name><name><surname>Studer</surname><given-names>V</given-names></name><name><surname>Dupuis</surname><given-names>JP</given-names></name><name><surname>Groc</surname><given-names>L</given-names></name><name><surname>Galland</surname><given-names>R</given-names></name><name><surname>Sibarita</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Multi-dimensional spectral single molecule localization microscopy</article-title><source>Frontiers in Bioinformatics</source><volume>2</volume><elocation-id>813494</elocation-id><pub-id pub-id-type="doi">10.3389/fbinf.2022.813494</pub-id><pub-id pub-id-type="pmid">36304321</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>LQ</given-names></name><name><surname>Yao</surname><given-names>SR</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>DG</given-names></name><name><surname>Fan</surname><given-names>YG</given-names></name><name><surname>Pan</surname><given-names>GX</given-names></name><name><surname>Tao</surname><given-names>SS</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>HF</given-names></name><name><surname>Wu</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>P2X7 receptor: A potential therapeutic target for autoimmune diseases</article-title><source>Autoimmunity Reviews</source><volume>18</volume><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2019.06.009</pub-id><pub-id pub-id-type="pmid">31181327</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HB</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>McLarnon</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>4957</fpage><lpage>4968</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5417-06.2007</pub-id><pub-id pub-id-type="pmid">17475804</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choquet</surname><given-names>D</given-names></name><name><surname>Sainlos</surname><given-names>M</given-names></name><name><surname>Sibarita</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Advanced imaging and labelling methods to decipher brain cell organization and function</article-title><source>Nature Reviews. Neuroscience</source><volume>22</volume><fpage>237</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/s41583-021-00441-z</pub-id><pub-id pub-id-type="pmid">33712727</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F</given-names></name><name><surname>Dal Ben</surname><given-names>D</given-names></name><name><surname>Sarti</surname><given-names>AC</given-names></name><name><surname>Giuliani</surname><given-names>AL</given-names></name><name><surname>Falzoni</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The P2X7 receptor in infection and inflammation</article-title><source>Immunity</source><volume>47</volume><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.020</pub-id><pub-id pub-id-type="pmid">28723547</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douguet</surname><given-names>L</given-names></name><name><surname>Janho Dit Hreich</surname><given-names>S</given-names></name><name><surname>Benzaquen</surname><given-names>J</given-names></name><name><surname>Seguin</surname><given-names>L</given-names></name><name><surname>Juhel</surname><given-names>T</given-names></name><name><surname>Dezitter</surname><given-names>X</given-names></name><name><surname>Duranton</surname><given-names>C</given-names></name><name><surname>Ryffel</surname><given-names>B</given-names></name><name><surname>Kanellopoulos</surname><given-names>J</given-names></name><name><surname>Delarasse</surname><given-names>C</given-names></name><name><surname>Renault</surname><given-names>N</given-names></name><name><surname>Furman</surname><given-names>C</given-names></name><name><surname>Homerin</surname><given-names>G</given-names></name><name><surname>Féral</surname><given-names>C</given-names></name><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Millet</surname><given-names>R</given-names></name><name><surname>Adriouch</surname><given-names>S</given-names></name><name><surname>Ghinet</surname><given-names>A</given-names></name><name><surname>Hofman</surname><given-names>P</given-names></name><name><surname>Vouret-Craviari</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>653</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-20912-2</pub-id><pub-id pub-id-type="pmid">33510147</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>K</given-names></name><name><surname>Martz</surname><given-names>A</given-names></name><name><surname>Peralta</surname><given-names>FA</given-names></name><name><surname>Cevoli</surname><given-names>F</given-names></name><name><surname>Boué-Grabot</surname><given-names>E</given-names></name><name><surname>Compan</surname><given-names>V</given-names></name><name><surname>Gautherat</surname><given-names>F</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name><name><surname>Chataigneau</surname><given-names>T</given-names></name><name><surname>Grutter</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>P2X7 receptors and TMEM16 channels are functionally coupled with implications for macropore formation and current facilitation</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>6542</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22126542</pub-id><pub-id pub-id-type="pmid">34207150</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelstein</surname><given-names>AD</given-names></name><name><surname>Tsuchida</surname><given-names>MA</given-names></name><name><surname>Amodaj</surname><given-names>N</given-names></name><name><surname>Pinkard</surname><given-names>H</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name><name><surname>Stuurman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Advanced methods of microscope control using μManager software</article-title><source>Journal of Biological Methods</source><volume>1</volume><elocation-id>e10</elocation-id><pub-id pub-id-type="doi">10.14440/jbm.2014.36</pub-id><pub-id pub-id-type="pmid">25606571</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density</article-title><source>Nature Reviews. Neuroscience</source><volume>10</volume><fpage>87</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nrn2540</pub-id><pub-id pub-id-type="pmid">19153575</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D</given-names></name><name><surname>Villalba</surname><given-names>M</given-names></name><name><surname>Chiozzi</surname><given-names>P</given-names></name><name><surname>Falzoni</surname><given-names>S</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Mouse microglial cells express a plasma membrane pore gated by extracellular ATP</article-title><source>Journal of Immunology</source><volume>156</volume><fpage>1531</fpage><lpage>1539</lpage><pub-id pub-id-type="pmid">8568257</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D</given-names></name><name><surname>Chiozzi</surname><given-names>P</given-names></name><name><surname>Falzoni</surname><given-names>S</given-names></name><name><surname>Dal Susino</surname><given-names>M</given-names></name><name><surname>Melchiorri</surname><given-names>L</given-names></name><name><surname>Baricordi</surname><given-names>OR</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages</article-title><source>Journal of Immunology</source><volume>159</volume><fpage>1451</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">9233643</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D</given-names></name><name><surname>Pizzirani</surname><given-names>C</given-names></name><name><surname>Adinolfi</surname><given-names>E</given-names></name><name><surname>Lemoli</surname><given-names>RM</given-names></name><name><surname>Curti</surname><given-names>A</given-names></name><name><surname>Idzko</surname><given-names>M</given-names></name><name><surname>Panther</surname><given-names>E</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The P2X7 Receptor: A key player in IL-1 processing and release</article-title><source>The Journal of Immunology</source><volume>176</volume><fpage>3877</fpage><lpage>3883</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.7.3877</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Capece</surname><given-names>M</given-names></name><name><surname>Chiozzi</surname><given-names>P</given-names></name><name><surname>Falzoni</surname><given-names>S</given-names></name><name><surname>Sanz</surname><given-names>JM</given-names></name><name><surname>Sarti</surname><given-names>AC</given-names></name><name><surname>Bonora</surname><given-names>M</given-names></name><name><surname>Pinton</surname><given-names>P</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein</article-title><source>FASEB Journal</source><volume>29</volume><fpage>2450</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1096/fj.14-268714</pub-id><pub-id pub-id-type="pmid">25690658</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangadharan</surname><given-names>V</given-names></name><name><surname>Nohe</surname><given-names>A</given-names></name><name><surname>Caplan</surname><given-names>J</given-names></name><name><surname>Czymmek</surname><given-names>K</given-names></name><name><surname>Duncan</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Caveolin-1 regulates P2X7 receptor signaling in osteoblasts</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>308</volume><fpage>C41</fpage><lpage>C50</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00037.2014</pub-id><pub-id pub-id-type="pmid">25318104</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Marcos</surname><given-names>M</given-names></name><name><surname>Pochet</surname><given-names>S</given-names></name><name><surname>Marino</surname><given-names>A</given-names></name><name><surname>Dehaye</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>P2X7 and phospholipid signalling: the search of the “missing link” in epithelial cells</article-title><source>Cellular Signalling</source><volume>18</volume><fpage>2098</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2006.05.008</pub-id><pub-id pub-id-type="pmid">16815675</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Marcos</surname><given-names>M</given-names></name><name><surname>Pochet</surname><given-names>S</given-names></name><name><surname>Tandel</surname><given-names>S</given-names></name><name><surname>Fontanils</surname><given-names>U</given-names></name><name><surname>Astigarraga</surname><given-names>E</given-names></name><name><surname>Fernández-González</surname><given-names>JA</given-names></name><name><surname>Kumps</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>A</given-names></name><name><surname>Dehaye</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization and comparison of raft-like membranes isolated by two different methods from rat submandibular gland cells</article-title><source>Biochimica et Biophysica Acta (BBA) - Biomembranes</source><volume>1758</volume><fpage>796</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2006.05.008</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glushonkov</surname><given-names>O</given-names></name><name><surname>Réal</surname><given-names>E</given-names></name><name><surname>Boutant</surname><given-names>E</given-names></name><name><surname>Mély</surname><given-names>Y</given-names></name><name><surname>Didier</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Optimized protocol for combined PALM-dSTORM imaging</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>8749</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27059-z</pub-id><pub-id pub-id-type="pmid">29884886</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonnord</surname><given-names>P</given-names></name><name><surname>Delarasse</surname><given-names>C</given-names></name><name><surname>Auger</surname><given-names>R</given-names></name><name><surname>Benihoud</surname><given-names>K</given-names></name><name><surname>Prigent</surname><given-names>M</given-names></name><name><surname>Cuif</surname><given-names>MH</given-names></name><name><surname>Lamaze</surname><given-names>C</given-names></name><name><surname>Kanellopoulos</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts</article-title><source>FASEB Journal</source><volume>23</volume><fpage>795</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1096/fj.08-114637</pub-id><pub-id pub-id-type="pmid">18971257</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guile</surname><given-names>SD</given-names></name><name><surname>Alcaraz</surname><given-names>L</given-names></name><name><surname>Birkinshaw</surname><given-names>TN</given-names></name><name><surname>Bowers</surname><given-names>KC</given-names></name><name><surname>Ebden</surname><given-names>MR</given-names></name><name><surname>Furber</surname><given-names>M</given-names></name><name><surname>Stocks</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Antagonists of the P2X(7) receptor. From lead identification to drug development</article-title><source>Journal of Medicinal Chemistry</source><volume>52</volume><fpage>3123</fpage><lpage>3141</lpage><pub-id pub-id-type="doi">10.1021/jm801528x</pub-id><pub-id pub-id-type="pmid">19191585</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habermacher</surname><given-names>C</given-names></name><name><surname>Martz</surname><given-names>A</given-names></name><name><surname>Calimet</surname><given-names>N</given-names></name><name><surname>Lemoine</surname><given-names>D</given-names></name><name><surname>Peverini</surname><given-names>L</given-names></name><name><surname>Specht</surname><given-names>A</given-names></name><name><surname>Cecchini</surname><given-names>M</given-names></name><name><surname>Grutter</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Photo-switchable tweezers illuminate pore-opening motions of an ATP-gated P2X ion channel</article-title><source>eLife</source><volume>5</volume><elocation-id>e11050</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11050</pub-id><pub-id pub-id-type="pmid">26808983</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Fourgeaud</surname><given-names>L</given-names></name><name><surname>Bhattacharya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of microglial P2X7: modulation of cell death and cytokine release</article-title><source>Journal of Neuroinflammation</source><volume>14</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-017-0904-8</pub-id><pub-id pub-id-type="pmid">28716092</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>P2X7 receptor as a potential target for major depressive disorder</article-title><source>Current Drug Targets</source><volume>22</volume><fpage>1108</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.2174/1389450122666210120141908</pub-id><pub-id pub-id-type="pmid">33494675</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Nie</surname><given-names>X</given-names></name><name><surname>Bian</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Disruption of the Na+/K+-ATPase-purinergic P2X7 receptor complex in microglia promotes stress-induced anxiety</article-title><source>Immunity</source><volume>57</volume><fpage>495</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.01.018</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyre</surname><given-names>DE</given-names></name><name><surname>Le Trong</surname><given-names>I</given-names></name><name><surname>Merritt</surname><given-names>EA</given-names></name><name><surname>Eccleston</surname><given-names>JF</given-names></name><name><surname>Green</surname><given-names>NM</given-names></name><name><surname>Stenkamp</surname><given-names>RE</given-names></name><name><surname>Stayton</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cooperative hydrogen bond interactions in the streptavidin-biotin system</article-title><source>Protein Science</source><volume>15</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1110/ps.051970306</pub-id><pub-id pub-id-type="pmid">16452627</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>TM</given-names></name><name><surname>Rubini</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuronal P2X7 receptors revisited: Do they really exist?</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>7049</fpage><lpage>7062</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3103-16.2017</pub-id><pub-id pub-id-type="pmid">28747388</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>P2X7 receptors amplify CNS damage in neurodegenerative diseases</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>5996</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21175996</pub-id><pub-id pub-id-type="pmid">32825423</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname><given-names>P</given-names></name><name><surname>Müller</surname><given-names>CE</given-names></name><name><surname>Jacobson</surname><given-names>KA</given-names></name><name><surname>Grutter</surname><given-names>T</given-names></name><name><surname>Nicke</surname><given-names>A</given-names></name><name><surname>Fountain</surname><given-names>SJ</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Schmalzing</surname><given-names>G</given-names></name><name><surname>Jarvis</surname><given-names>MF</given-names></name><name><surname>Stojilkovic</surname><given-names>SS</given-names></name><name><surname>King</surname><given-names>BF</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Update of P2X receptor properties and their pharmacology: IUPHAR Review 30</article-title><source>British Journal of Pharmacology</source><volume>178</volume><fpage>489</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1111/bph.15299</pub-id><pub-id pub-id-type="pmid">33125712</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors</article-title><source>Biochemical Pharmacology</source><volume>187</volume><elocation-id>114309</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114309</pub-id><pub-id pub-id-type="pmid">33130129</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>KA</given-names></name><name><surname>Delicado</surname><given-names>EG</given-names></name><name><surname>Gachet</surname><given-names>C</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>von Kügelgen</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Miras-Portugal</surname><given-names>MT</given-names></name><name><surname>Novak</surname><given-names>I</given-names></name><name><surname>Schöneberg</surname><given-names>T</given-names></name><name><surname>Perez-Sen</surname><given-names>R</given-names></name><name><surname>Thor</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Müller</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Update of P2Y receptor pharmacology: IUPHAR review 27</article-title><source>British Journal of Pharmacology</source><volume>177</volume><fpage>2413</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1111/bph.15005</pub-id><pub-id pub-id-type="pmid">32037507</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janks</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>CVR</given-names></name><name><surname>Egan</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A central role for P2X7 receptors in human microglia</article-title><source>Journal of Neuroinflammation</source><volume>15</volume><elocation-id>325</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-018-1353-8</pub-id><pub-id pub-id-type="pmid">30463629</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarek-Hájek</surname><given-names>K</given-names></name><name><surname>Lörinczi</surname><given-names>E</given-names></name><name><surname>Hausmann</surname><given-names>R</given-names></name><name><surname>Nicke</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular and functional properties of P2X receptors--recent progress and persisting challenges</article-title><source>Purinergic Signalling</source><volume>8</volume><fpage>375</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1007/s11302-012-9314-7</pub-id><pub-id pub-id-type="pmid">22547202</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarek-Hajek</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kopp</surname><given-names>R</given-names></name><name><surname>Grosche</surname><given-names>A</given-names></name><name><surname>Rissiek</surname><given-names>B</given-names></name><name><surname>Saul</surname><given-names>A</given-names></name><name><surname>Bruzzone</surname><given-names>S</given-names></name><name><surname>Engel</surname><given-names>T</given-names></name><name><surname>Jooss</surname><given-names>T</given-names></name><name><surname>Krautloher</surname><given-names>A</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Magnus</surname><given-names>T</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Sirko</surname><given-names>S</given-names></name><name><surname>Koch-Nolte</surname><given-names>F</given-names></name><name><surname>Eulenburg</surname><given-names>V</given-names></name><name><surname>Nicke</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody</article-title><source>eLife</source><volume>7</volume><elocation-id>e36217</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.36217</pub-id><pub-id pub-id-type="pmid">30074479</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>LK</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Drummond</surname><given-names>K</given-names></name><name><surname>O’Brien</surname><given-names>T</given-names></name><name><surname>Monif</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of microglia and P2X7 receptors in gliomas</article-title><source>Journal of Neuroimmunology</source><volume>332</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.04.010</pub-id><pub-id pub-id-type="pmid">31031209</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasawa</surname><given-names>A</given-names></name><name><surname>Kawate</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structural basis for subtype-specific inhibition of the P2X7 receptor</article-title><source>eLife</source><volume>5</volume><elocation-id>e22153</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.22153</pub-id><pub-id pub-id-type="pmid">27935479</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasawa</surname><given-names>A</given-names></name><name><surname>Kawate</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Expression and purification of a mammalian P2X7 receptor from Sf9 insect cells</article-title><source>BIO-PROTOCOL</source><volume>7</volume><elocation-id>e2544</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2544</pub-id><pub-id pub-id-type="pmid">28966946</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levet</surname><given-names>F</given-names></name><name><surname>Hosy</surname><given-names>E</given-names></name><name><surname>Kechkar</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>C</given-names></name><name><surname>Beghin</surname><given-names>A</given-names></name><name><surname>Choquet</surname><given-names>D</given-names></name><name><surname>Sibarita</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SR-Tesseler: a method to segment and quantify localization-based super-resolution microscopy data</article-title><source>Nature Methods</source><volume>12</volume><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3579</pub-id><pub-id pub-id-type="pmid">26344046</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>B</given-names></name><name><surname>Ameriks</surname><given-names>MK</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Fourgeaud</surname><given-names>L</given-names></name><name><surname>Vliegen</surname><given-names>M</given-names></name><name><surname>Verluyten</surname><given-names>W</given-names></name><name><surname>Haspeslagh</surname><given-names>P</given-names></name><name><surname>Carruthers</surname><given-names>NI</given-names></name><name><surname>Lovenberg</surname><given-names>TW</given-names></name><name><surname>Bonaventure</surname><given-names>P</given-names></name><name><surname>Letavic</surname><given-names>MA</given-names></name><name><surname>Bhattacharya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334</article-title><source>European Journal of Pharmacology</source><volume>765</volume><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.09.026</pub-id><pub-id pub-id-type="pmid">26386289</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>BN</given-names></name><name><surname>Groves</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Spatial organization and signal transduction at intercellular junctions</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>11</volume><fpage>342</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/nrm2883</pub-id><pub-id pub-id-type="pmid">20354536</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Amar</surname><given-names>M</given-names></name><name><surname>Dalle</surname><given-names>C</given-names></name><name><surname>Youssef</surname><given-names>I</given-names></name><name><surname>Boucher</surname><given-names>C</given-names></name><name><surname>Le Duigou</surname><given-names>C</given-names></name><name><surname>Brückner</surname><given-names>M</given-names></name><name><surname>Prigent</surname><given-names>A</given-names></name><name><surname>Sazdovitch</surname><given-names>V</given-names></name><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Kanellopoulos</surname><given-names>JM</given-names></name><name><surname>Fontaine</surname><given-names>B</given-names></name><name><surname>Delatour</surname><given-names>B</given-names></name><name><surname>Delarasse</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>New role of P2X7 receptor in an Alzheimer’s disease mouse model</article-title><source>Molecular Psychiatry</source><volume>24</volume><fpage>108</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0108-3</pub-id><pub-id pub-id-type="pmid">29934546</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>AE</given-names></name><name><surname>Yoshioka</surname><given-names>C</given-names></name><name><surname>Mansoor</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Full-Length P2X<sub>7</sub> structures reveal how palmitoylation prevents channel desensitization</article-title><source>Cell</source><volume>179</volume><fpage>659</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.017</pub-id><pub-id pub-id-type="pmid">31587896</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>AD</given-names></name><name><surname>Chambers</surname><given-names>LJ</given-names></name><name><surname>Clay</surname><given-names>WC</given-names></name><name><surname>Condreay</surname><given-names>JP</given-names></name><name><surname>Walter</surname><given-names>DS</given-names></name><name><surname>Chessell</surname><given-names>IP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding</article-title><source>British Journal of Pharmacology</source><volume>151</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707196</pub-id><pub-id pub-id-type="pmid">17339830</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miras-Portugal</surname><given-names>MT</given-names></name><name><surname>Sebastián-Serrano</surname><given-names>Á</given-names></name><name><surname>de Diego García</surname><given-names>L</given-names></name><name><surname>Díaz-Hernández</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuronal P2X7 receptor: Involvement in neuronal physiology and pathology</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>7063</fpage><lpage>7072</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3104-16.2017</pub-id><pub-id pub-id-type="pmid">28747389</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monif</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>CA</given-names></name><name><surname>Powell</surname><given-names>KL</given-names></name><name><surname>Smart</surname><given-names>ML</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>3781</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5512-08.2009</pub-id><pub-id pub-id-type="pmid">19321774</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monif</surname><given-names>M</given-names></name><name><surname>Burnstock</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Microglia: proliferation and activation driven by the P2X7 receptor</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>42</volume><fpage>1753</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2010.06.021</pub-id><pub-id pub-id-type="pmid">20599520</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monif</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>CA</given-names></name><name><surname>Powell</surname><given-names>KL</given-names></name><name><surname>Drummond</surname><given-names>KJ</given-names></name><name><surname>O’Brien</surname><given-names>TJ</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interleukin-1β has trophic effects in microglia and its release is mediated by P2X7R pore</article-title><source>Journal of Neuroinflammation</source><volume>13</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-016-0621-8</pub-id><pub-id pub-id-type="pmid">27364756</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Molecular physiology of P2X receptors</article-title><source>Physiological Reviews</source><volume>82</volume><fpage>1013</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1152/physrev.00015.2002</pub-id><pub-id pub-id-type="pmid">12270951</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>N</given-names></name><name><surname>Keller</surname><given-names>D</given-names></name><name><surname>Rajan</surname><given-names>VS</given-names></name><name><surname>Gönczy</surname><given-names>P</given-names></name><name><surname>Manley</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Simple buffers for 3D STORM microscopy</article-title><source>Biomedical Optics Express</source><volume>4</volume><fpage>885</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1364/BOE.4.000885</pub-id><pub-id pub-id-type="pmid">23761850</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovesný</surname><given-names>M</given-names></name><name><surname>Křížek</surname><given-names>P</given-names></name><name><surname>Borkovec</surname><given-names>J</given-names></name><name><surname>Svindrych</surname><given-names>Z</given-names></name><name><surname>Hagen</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2389</fpage><lpage>2390</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu202</pub-id><pub-id pub-id-type="pmid">24771516</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perregaux</surname><given-names>DG</given-names></name><name><surname>McNiff</surname><given-names>P</given-names></name><name><surname>Laliberte</surname><given-names>R</given-names></name><name><surname>Conklyn</surname><given-names>M</given-names></name><name><surname>Gabel</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood</article-title><source>Journal of Immunology</source><volume>165</volume><fpage>4615</fpage><lpage>4623</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.8.4615</pub-id><pub-id pub-id-type="pmid">11035104</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raouf</surname><given-names>R</given-names></name><name><surname>Chabot-Doré</surname><given-names>A-J</given-names></name><name><surname>Ase</surname><given-names>AR</given-names></name><name><surname>Blais</surname><given-names>D</given-names></name><name><surname>Séguéla</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Differential regulation of microglial P2X4 and P2X7 ATP receptors following LPS-induced activation</article-title><source>Neuropharmacology</source><volume>53</volume><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2007.06.010</pub-id><pub-id pub-id-type="pmid">17675190</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>D</given-names></name><name><surname>Hernández-Hernández</surname><given-names>G</given-names></name><name><surname>Matsumoto</surname><given-names>C</given-names></name><name><surname>Tajada</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>CM</given-names></name><name><surname>Dixon</surname><given-names>RE</given-names></name><name><surname>O’Dwyer</surname><given-names>S</given-names></name><name><surname>Navedo</surname><given-names>MF</given-names></name><name><surname>Trimmer</surname><given-names>JS</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Binder</surname><given-names>MD</given-names></name><name><surname>Santana</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A stochastic model of ion channel cluster formation in the plasma membrane</article-title><source>The Journal of General Physiology</source><volume>151</volume><fpage>1116</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1085/jgp.201912327</pub-id><pub-id pub-id-type="pmid">31371391</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schermelleh</surname><given-names>L</given-names></name><name><surname>Ferrand</surname><given-names>A</given-names></name><name><surname>Huser</surname><given-names>T</given-names></name><name><surname>Eggeling</surname><given-names>C</given-names></name><name><surname>Sauer</surname><given-names>M</given-names></name><name><surname>Biehlmaier</surname><given-names>O</given-names></name><name><surname>Drummen</surname><given-names>GPC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Super-resolution microscopy demystified</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0251-8</pub-id><pub-id pub-id-type="pmid">30602772</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraiwa</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Nonaka</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Hamachi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Chemical tools for endogenous protein labeling and profiling</article-title><source>Cell Chemical Biology</source><volume>27</volume><fpage>970</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2020.06.016</pub-id><pub-id pub-id-type="pmid">32679042</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>AN</given-names></name><name><surname>Rodriguez</surname><given-names>PC</given-names></name><name><surname>Triller</surname><given-names>A</given-names></name><name><surname>Renner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic micro-organization of P2X7 receptors revealed by PALM based single particle tracking</article-title><source>Frontiers in Cellular Neuroscience</source><volume>7</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2013.00232</pub-id><pub-id pub-id-type="pmid">24324402</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieber</surname><given-names>JJ</given-names></name><name><surname>Willig</surname><given-names>KI</given-names></name><name><surname>Kutzner</surname><given-names>C</given-names></name><name><surname>Gerding-Reimers</surname><given-names>C</given-names></name><name><surname>Harke</surname><given-names>B</given-names></name><name><surname>Donnert</surname><given-names>G</given-names></name><name><surname>Rammner</surname><given-names>B</given-names></name><name><surname>Eggeling</surname><given-names>C</given-names></name><name><surname>Hell</surname><given-names>SW</given-names></name><name><surname>Grubmüller</surname><given-names>H</given-names></name><name><surname>Lang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Anatomy and dynamics of a supramolecular membrane protein cluster</article-title><source>Science</source><volume>317</volume><fpage>1072</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1126/science.1141727</pub-id><pub-id pub-id-type="pmid">17717182</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra-Marquez</surname><given-names>J</given-names></name><name><surname>Schaller</surname><given-names>L</given-names></name><name><surname>Sassenbach</surname><given-names>L</given-names></name><name><surname>Ramírez-Fernández</surname><given-names>A</given-names></name><name><surname>Alt</surname><given-names>P</given-names></name><name><surname>Rissiek</surname><given-names>B</given-names></name><name><surname>Zimmer</surname><given-names>B</given-names></name><name><surname>Schredelseker</surname><given-names>J</given-names></name><name><surname>Hector</surname><given-names>J</given-names></name><name><surname>Stähler</surname><given-names>T</given-names></name><name><surname>Koch-Nolte</surname><given-names>F</given-names></name><name><surname>Staab-Weijnitz</surname><given-names>CA</given-names></name><name><surname>Dietrich</surname><given-names>A</given-names></name><name><surname>Kopp</surname><given-names>R</given-names></name><name><surname>Nicke</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Different localization of P2X4 and P2X7 receptors in native mouse lung - lack of evidence for a direct P2X4-P2X7 receptor interaction</article-title><source>Frontiers in Immunology</source><volume>15</volume><elocation-id>1425938</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1425938</pub-id><pub-id pub-id-type="pmid">38953020</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>JA</given-names></name><name><surname>Young</surname><given-names>MT</given-names></name><name><surname>Sung</surname><given-names>HY</given-names></name><name><surname>North</surname><given-names>RA</given-names></name><name><surname>Surprenant</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Reanalysis of P2X7 receptor expression in rodent brain</article-title><source>The Journal of Neuroscience</source><volume>24</volume><fpage>6307</fpage><lpage>6314</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1469-04.2004</pub-id><pub-id pub-id-type="pmid">15254086</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Ikonen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Functional rafts in cell membranes</article-title><source>Nature</source><volume>387</volume><fpage>569</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/42408</pub-id><pub-id pub-id-type="pmid">9177342</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surprenant</surname><given-names>A</given-names></name><name><surname>Rassendren</surname><given-names>F</given-names></name><name><surname>Kawashima</surname><given-names>E</given-names></name><name><surname>North</surname><given-names>RA</given-names></name><name><surname>Buell</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)</article-title><source>Science</source><volume>272</volume><fpage>735</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1126/science.272.5262.735</pub-id><pub-id pub-id-type="pmid">8614837</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>KV</given-names></name><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Ting</surname><given-names>JP-Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The NLRP3 inflammasome: molecular activation and regulation to therapeutics</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>477</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0165-0</pub-id><pub-id pub-id-type="pmid">31036962</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Tsukidate</surname><given-names>T</given-names></name><name><surname>Shapira</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>Y</given-names></name><name><surname>Fujisawa</surname><given-names>A</given-names></name><name><surname>Hamachi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rapid labelling and covalent inhibition of intracellular native proteins using ligand-directed N-acyl-N-alkyl sulfonamide</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1870</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04343-0</pub-id><pub-id pub-id-type="pmid">29760386</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trang</surname><given-names>M</given-names></name><name><surname>Schmalzing</surname><given-names>G</given-names></name><name><surname>Müller</surname><given-names>CE</given-names></name><name><surname>Markwardt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dissection of P2X4 and P2X7 receptor current components in BV-2 Microglia</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>8489</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21228489</pub-id><pub-id pub-id-type="pmid">33187309</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volonté</surname><given-names>C</given-names></name><name><surname>Apolloni</surname><given-names>S</given-names></name><name><surname>Skaper</surname><given-names>SD</given-names></name><name><surname>Burnstock</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>P2X7 receptors: channels, pores and more</article-title><source>CNS &amp; Neurological Disorders Drug Targets</source><volume>11</volume><fpage>705</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.2174/187152712803581137</pub-id><pub-id pub-id-type="pmid">22963440</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinhold</surname><given-names>K</given-names></name><name><surname>Krause-Buchholz</surname><given-names>U</given-names></name><name><surname>Rödel</surname><given-names>G</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name><name><surname>Barth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interaction and interrelation of P2X7 and P2X4 receptor complexes in mouse lung epithelial cells</article-title><source>Cellular and Molecular Life Sciences</source><volume>67</volume><fpage>2631</fpage><lpage>2642</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0355-1</pub-id><pub-id pub-id-type="pmid">20405163</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Higher-order transient structures and the principle of dynamic connectivity in membrane signaling</article-title><source>PNAS</source><volume>122</volume><elocation-id>e2421280121</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2421280121</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Yuxi</given-names></name><name><surname>Mazal</surname><given-names>H</given-names></name><name><surname>Mandala</surname><given-names>VS</given-names></name><name><surname>Pérez-Mitta</surname><given-names>G</given-names></name><name><surname>Sondoghdar</surname><given-names>V</given-names></name><name><surname>Haselwandter</surname><given-names>CA</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Higher-order transient membrane protein structures</article-title><source>PNAS</source><volume>122</volume><elocation-id>e2421275121</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2421275121</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106096.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pless</surname><given-names>Stephan A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Copenhagen</institution><country>Denmark</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>The authors employ an unbiased, affinity-guided reagent to label P2X7 receptor and use super-resolution imaging to monitor P2X7 redistribution in response to inflammatory signaling. The evidence is <bold>convincing</bold> and the study will be <bold>valuable</bold> to those studying the dynamics of receptor distribution and clustering.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106096.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this paper, the authors developed a chemical labeling reagent for P2X7 receptors, called X7-uP. This labeling reagent selectively labels endogenous P2X7 receptors with biotin based on ligand-directed NASA chemistry. After labeling the endogenous P2X7 receptor with biotin, the receptor can be fluorescently labeled with streptavidin-AlexaFluor647. The authors carefully examined the binding properties and labeling selectivity of X7-uP to P2X7, characterized the labeling site of P2X7 receptors, and demonstrated fluorescence imaging of P2X7 receptors. The data obtained by SDS-PAGE, Western blot, and fluorescence microscopy clearly shows that X7-uP labels the P2X7 receptor. Finally, the authors fluorescently labeled the endogenous P2X7 in BV2 cells, which are a murine microglia model, and used dSTORM to reveal a nanoscale P2X7 redistribution mechanism under inflammatory conditions at high resolution.</p><p>Strengths:</p><p>X7-uP selectively labels endogenous P2X7 receptors with biotin. Streptavidin-AlexaFluor647 binds to the biotin labeled to the P2X7 receptor, allowing visualization of endogenous P2X7 receptors.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106096.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, Arnould et. al. develop an unbiased, affinity-guided reagent to label P2X7 receptor and use super-resolution imaging to monitor P2X7 redistribution in response to inflammatory signaling.</p><p>Strengths:</p><p>I think the X7-uP probe that they developed is very useful for visualizing localization of P2X7 receptor. They convincingly show that under inflammatory conditions, there is a reorganization of P2X7 localization into receptor clusters. Moreover, I think they have shown a very clever way to specifically label any receptor of interest. This has broad appeal.</p><p>I think the authors have done a very nice job addressing my original concerns. Here are those original concerns and my new comments related to how the authors address them.</p><p>(1) While the authors state that chemical modification of AZ10606120 to produce the X7-UP reagent has &quot;minimal impact&quot; on the inhibition of P2X7, we can see from Figure 2A and 2B that it does not antagonize P2X7 as effectively as the original antagonist. For the sake of completeness and quantitation, I think it would be great if the authors could determine the IC50 for X7-uP and compare it to the IC50 of AZ10606120.</p><p>The authors now show the relative inhibition of X7-uP compared to AZ10606120 at different concentrations. This provides a nice comparison to give the reader an idea of how effectively X7-uP inhibits P2X7 receptor. This is great.</p><p>(2) Do the authors know whether modification of the lysines with biotin affects the receptor's affinity for ATP (or ability to be activated by ATP)? What about P2X7 that has been modified with biotin and then labeled with Alexa 647? For the sake of completeness and quantitation, I think it would be great if the authors could determine the EC50 of biotinylated P2X7 for ATP as well as biotinylated and then Alexa 647 labeled P2X7 for ATP and compare these values to the affinity of unmodified WT P2X7 for ATP.</p><p>I agree with the authors that assessing the functional integrity of P2X7 following biotinylation and fluorophore labeling is outside the scope of this paper but would be important for studies involving dynamic or post-labeling functional analyses such as live trafficking.</p><p>(3) It is a little misleading to color the fluorescence signal from mScarlet green (for example, in Figure 3 and Figure 4). The fluorescence is not at the same wavelength as GFP. In fact, the wavelength (570 nm - 610 nm) for emission is closer to orange/red than to green. I think this color should be changed to differentiate the signal of mScarlet from the GFP signal used for each of the other P2X receptor subtypes.</p><p>The authors have now changed the mScarlet color to orange, which solves my concern.</p><p>(4) It is my understanding that P2X6 does not form homotrimers. Thus, I was a little surprised to see that the density and distribution of P2X6-GFP in Figure 3 looks very similar to the density and distribution of the other P2X subtypes. Do the authors have an explanation for this? Are they looking at P2X6 protomers inserted into the plasma membrane? Does the cell line have endogenous P2X receptor subtypes? Is Figure 3 showing heterotrimers with P2X6 receptor? A little explanation might be helpful.</p><p>The authors address this point very well and include nice data to show that P2X6 does not insert into the plasma membrane as a homotrimer.</p><p>(5) It is easy to overlook the fact that the antagonist leaves the binding pocket once the biotin has been attached to the lysines. It might be helpful if the authors made this a little more apparent in Figure 1 or in the text describing the NASA chemistry reaction.</p><p>The authors have modified Figure 1 to make it easier to understand the NASA chemistry reaction.</p><p>I congratulate the authors on an outstanding paper!</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106096.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arnould</surname><given-names>Benoit</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Martz</surname><given-names>Adeline</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Belzanne</surname><given-names>Pauline</given-names></name><role specific-use="author">Author</role><aff><institution>Centre National de la Recherche Scientifique</institution><addr-line><named-content content-type="city">Bordeaux</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Peralta</surname><given-names>Francisco Andrés</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Cevoli</surname><given-names>Federico</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Hovhannisyan</surname><given-names>Volodya</given-names></name><role specific-use="author">Author</role><aff><institution>CNRS-UPR 3212</institution><addr-line><named-content content-type="city">Strasbourg</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Goumon</surname><given-names>Yannick</given-names></name><role specific-use="author">Author</role><aff><institution>CNRS-UPR 3212</institution><addr-line><named-content content-type="city">Strasbourg</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Hosy</surname><given-names>Eric</given-names></name><role specific-use="author">Author</role><aff><institution>Univ Bordeaux, CNRS,UMR 5297</institution><addr-line><named-content content-type="city">Bordeaux</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Specht</surname><given-names>Alexandre</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Grutter</surname><given-names>Thomas</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Strasbourg, CNRS, UMR7199</institution><addr-line><named-content content-type="city">Illkirch</named-content></addr-line><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>In this paper, the authors developed a chemical labeling reagent for P2X7 receptors, called X7-uP. This labeling reagent selectively labels endogenous P2X7 receptors with biotin based on ligand-directed NASA chemistry (Ref. 41). After labeling the endogenous P2X7 receptor with biotin, the receptor can be fluorescently labeled with streptavidin-AlexaFluor647. The authors carefully examined the binding properties and labeling selectivity of X7-uP to P2X7, characterized the labeling site of P2X7 receptors, and demonstrated fluorescence imaging of P2X7 receptors. The data obtained by SDS-PAGE, Western blot, and fluorescence microscopy clearly show that X7-uP labels the P2X7 receptor. Finally, the authors fluorescently labeled the endogenous P2X7 in BV2 cells, which are a murine microglia model, and used dSTORM to reveal a nanoscale P2X7 redistribution mechanism under inflammatory conditions at high resolution.</p><p>Strengths:</p><p>X7-uP selectively labels endogenous P2X7 receptors with biotin. Streptavidin-AlexaFluor647 binds to the biotin labeled to the P2X7 receptor, allowing visualization of endogenous P2X7 receptors.</p></disp-quote><p>We thank the reviewer for their positive comment.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Weaknesses &amp; Comments</p><p>(1) The P2X7 receptor exists in a trimeric form. If it is not a monomer under the conditions of the pull-down assay in Figure 2C, the quantitative values may not be accurate.</p></disp-quote><p>We thank the reviewer for this comment. As shown in Figure 2C, the band observed on the denaturing SDS-PAGE corresponds to the monomeric form of the P2X7 receptor. While we cannot exclude the presence of non-monomeric species under native conditions, no such higher-order forms are visible in the gel. This observation supports the conclusion that the quantitative values presented are based on the monomeric form and are therefore reliable.</p><disp-quote content-type="editor-comment"><p>(2) In Figure 3, GFP fluorescence was observed in the cell. Are all types of P2X receptors really expressed on the cell surface ?</p></disp-quote><p>We thank the reviewer for this excellent comment, which was also raised by reviewer 2. To address this concern, we performed a commercial cell-surface protein biotinylation assay to assess whether GFP-tagged P2X receptors reach the plasma membrane. As expected, all P2X subtypes except P2X6 were detected at the cell surface in HEK293T cells, thereby validating our confocal fluorescence microscopy assay. These new data are now included in Figure 3 — figure supplement 1.</p><disp-quote content-type="editor-comment"><p>(3) The reviewer was not convinced of the advantages of the approach taken in this paper, because the endogenous receptor labeling in this study could also be done using conventional antibody-based labeling methods.</p></disp-quote><p>We thank the reviewer for raising this important point and would like to highlight several advantages of our approach compared to conventional antibody-based labeling.</p><p>First, commercially available P2X7 antibodies often suffer from poor specificity and are generally not suitable for reliably detecting endogenous P2X7 receptors, as documented in previous studies (e.g., PMID: 16564580 and PMID: 15254086). While recent advances have been made using nanobodies with improved specificity for P2X7 (e.g., PMID: 30074479 and PMID: 38953020), our strategy is distinct and complementary to nanobody-based approaches.</p><p>Second, antibodies rely on non-covalent interactions with the receptor, which can result in dissociation over time. In contrast, our X7-uP probe covalently biotinylates lysine residues on the P2X7 receptor through stable amide bond formation. This covalent labeling ensures that the biotin moiety remains permanently attached, an advantage not afforded by reversible binding strategies.</p><p>Third, by selectively biotinylating P2X7 receptors, our method provides a versatile platform for the chemical attachment of a wide range of probes or functional moieties. Although we did not demonstrate this application in the current study, we believe this modularity represents an additional advantage of our approach.</p><p>We have now revised the discussion to highlight these key advantages, allowing the reader to form their own opinion. We hope this addresses the reviewer’s concerns and clarifies the benefits of our approach.</p><disp-quote content-type="editor-comment"><p>(4) Although P2X7 was successfully labeled in this paper, it is not new as a chemistry. There is a need for more attractive functional evaluation such as live trafficking analysis of endogenous P2X7.</p></disp-quote><p>We agree with the reviewer that the underlying chemistry is not novel per se. However, to our knowledge, it has not previously been applied to the P2X7 receptor, and thus constitutes a novel application with specific relevance for studying native P2X7 biology.</p><p>We also appreciate the reviewer’s suggestion regarding live trafficking analysis of endogenous P2X7. While this is indeed a valuable and interesting direction, we believe it lies beyond the scope of the present study, as it would first require demonstrating that the labeling itself does not affect P2X7 function (see below). This important step would necessitate additional experiments, which we consider more appropriate for a follow-up investigation.</p><disp-quote content-type="editor-comment"><p>(5) The reviewer has concerns that the use of the large-size streptavidin to label the P2X7 receptor may perturbate the dynamics of the receptor.</p></disp-quote><p>We thank the reviewer for raising this important point. Although we did not directly measure receptor dynamics, it is indeed possible that tetrameric streptavidin (tStrept-A 647) could promote P2X7 clustering by cross-linking nearby receptors due to its tetravalency (see also point 7 raised by the reviewer). To address this concern, we performed additional dSTORM experiments using a monomeric form of streptavidin-Alexa 647 (mSA) (see PMID: 26979420). Owing to its reduced size and lack of tetravalency, mSA has been shown to minimize artificial crosslinking of synaptic receptors (PMID: 26979420). A drawback of using mSA, however, is that the monomeric form carries only two fluorophores (estimated degree of labeling, DOL ≈ 2, PMID: 26979420), whereas the tetrameric form, according to the manufacturer’s certificate of analysis (Invitrogen S21374), has an average DOL of three fluorophores per monomer, resulting in a total of ~12 fluorophores per streptavidin.</p><p>We tested three conditions with mSA incubation: (i) control BV2 cells (without X7-uP), (ii) untreated X7-uP-labeled BV2 cells, and (iii) X7-uP-labeled BV2 cells treated with LPS and ATP (using the same concentrations and incubation times described in the manuscript). As shown in Author response image 1, only LPS+ATP treatment induced a clear increase in the mean cluster density compared to quiescent (untreated) BV2 cells. This effect closely matches the results obtained with tStrept-A 647, supporting the conclusion the tetrameric streptavidin does not artificially promote P2X7 clustering. It is also possible that the cellular environment of BV2 microglia differs from the confined architecture of synapses, which may further explain why cross-linking effects are less pronounced in our system.</p><p>As expected, the overall fluorescence signal with mSA was about tenfold lower than with tStrept-A 647, consistent with the expected fluorophore stoichiometry. This lower signal may explain why the values for the untreated condition appeared slightly higher than for the control, although the difference was not statistically significant (P = 0.1455).</p><p>We hope these additional experiments adequately address the reviewer’s concerns.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>BV2 labeling with monomeric streptavidin–Alexa 647 (mSA).</title><p>(A) Bright-field and dSTORM images of BV2 cells labeled with mSA in the presence (untreated and LPS+ATP) or absence (control) of 1 µM X7-uP. Treatment: LPS (1 µg/mL for 24 hours) and ATP (1 mM for 30 minutes). Scale bars, 10 µm. Insets: Magnified dSTORM images. Scale bars, 1 µm.(B) Quantification of the number of localizations (n = 2 independent experiments). Bars represent mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons (P values are indicated above the graph).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106096-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(6) It is better to directly label Alexa647 to the P2X7 receptor to avoid functional perturbation of P2X7.</p></disp-quote><p>Directly labeling of Alexa647 to the P2X7 receptor would require the design and synthesis of a novel probe, which is currently not available. Implementing such a strategy would involve substantial new experimental work that lies beyond the scope of the present study.</p><disp-quote content-type="editor-comment"><p>(7) In all imaging experiments, the addition of streptavidin, which acts as a cross-linking agent, may induce P2X7 receptor clustering. This concern would be dispelled if the receptors were labeled with a fluorescent dye instead of biotin and observed.</p></disp-quote><p>We refer the reviewer to our response in point 5, where we addressed this concern by comparing tetrameric and monomeric streptavidin conjugates. As noted above (see also point 6), directly labeling the receptor with a fluorescent dye would require the development of a new probe, which is outside the scope of the present study.</p><disp-quote content-type="editor-comment"><p>(8) There are several mentions of microglia in this paper, even though they are not used. This can lead to misunderstanding for the reader. The author conducted functional analysis of the P2X7 receptor in BV-2 cells, which are a model cell line but not microglia themselves. The text should be reviewed again and corrected to remove the misleading parts that could lead to misunderstanding. e.g. P8. lines 361-364</p><p>First, it combines N-cyanomethyl NASA chemistry with the high-affinity AZ10606120 ligand, enabling rapid labeling in microglia (within 10 min)</p><p>P8. lines 372-373</p><p>Our results not only confirm P2X7 expression in microglia, as previously reported (6, 26-33), but also reveal its nanoscale localization at the cell surface using dSTORM.</p></disp-quote><p>We agree with the reviewer’s comment. We have now modified the text, including the title.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this manuscript, Arnould et. al. develop an unbiased, affinity-guided reagent to label P2X7 receptor and use super-resolution imaging to monitor P2X7 redistribution in response to inflammatory signaling.</p><p>Strengths:</p><p>I think the X7-uP probe that they developed is very useful for visualizing localization of P2X7 receptor. They convincingly show that under inflammatory conditions, there is a reorganization of P2X7 localization into receptor clusters. Moreover, I think they have shown a very clever way to specifically label any receptor of interest. This has broad appeal</p></disp-quote><p>We thank the reviewer for their positive comment.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Overall, the manuscript is novel and interesting. However, I do have some suggestions for improvement.</p><p>(1) While the authors state that chemical modification of AZ10606120 to produce the X7-UP reagent has &quot;minimal impact&quot; on the inhibition of P2X7, we can see from Figure 2A and 2B that it does not antagonize P2X7 as effectively as the original antagonist. For the sake of completeness and quantitation, I think it would be great if the authors could determine the IC50 for X7-uP and compare it to the IC50 of AZ10606120.</p></disp-quote><p>We thank the reviewer for this insightful comment. Unfortunately, due to the limited availability of X7-uP, we were not able to establish a complete concentration–response curve to determine its IC<sub>50</sub>, which would require testing at concentrations &gt;1 µM. Nevertheless, to estimate the effect of the modification, we assessed current inhibition at 300 µM X7-uP and compared it with the reported IC<sub>50</sub> of AZ10606120 (10 nM). Under these conditions, both compounds produced a similar level of inhibition, indicating that while the chemical modification reduces potency relative to AZ10606120, X7-uP still functions as an effective probe for P2X7. We have now included these data in Figure 2 and revised the text accordingly.</p><disp-quote content-type="editor-comment"><p>(2) Do the authors know whether modification of the lysines with biotin affects the receptor's affinity for ATP (or ability to be activated by ATP)? What about P2X7 that has been modified with biotin and then labeled with Alexa 647? For the sake of completeness and quantitation, I think it would be great if the authors could determine the EC50 of biotinylated P2X7 for ATP as well as biotinylated and then Alexa 647 labeled P2X7 for ATP and compare these values to the affinity of unmodified WT P2X7 for ATP.</p></disp-quote><p>We thank the reviewer for raising this important point. At present, we have not determined whether modification of lysine residues with biotin, or subsequent labeling with Alexa647, affects the ATP sensitivity or functional properties of P2X7. However, we believe this does not impact the conclusions of the current study, as all functional assays were conducted prior to X7-uP labeling. The labeling is used here as a terminal &quot;snapshot&quot; to visualize the endogenous receptor without interfering with the functional characterization.</p><p>We fully agree that assessing the functional integrity of P2X7 following biotinylation and fluorophore labeling—such as by determining the EC<sub>50</sub> for ATP—would be essential for studies involving dynamic or post-labeling functional analyses, such as live trafficking. However, as noted earlier in our response to Reviewer 1 (point 4), these experiments lie beyond the scope of the current study.</p><disp-quote content-type="editor-comment"><p>(3) It is a little misleading to color the fluorescence signal from mScarlet green (for example, in Figure 3 and Figure 4). The fluorescence is not at the same wavelength as GFP. In fact, the wavelength (570 nm - 610 nm) for emission is closer to orange/red than to green. I think this color should be changed to differentiate the signal of mScarlet from the GFP signal used for each of the other P2X receptor subtypes.</p></disp-quote><p>As suggested, we changed the mScarlet color to orange for all relevant figures.</p><disp-quote content-type="editor-comment"><p>(4) It is my understanding that P2X6 does not form homotrimers. Thus, I was a little surprised to see that the density and distribution of P2X6-GFP in Figure 3 looks very similar to the density and distribution of the other P2X subtypes. Do the authors have an explanation for this? Are they looking at P2X6 protomers inserted into the plasma membrane? Does the cell line have endogenous P2X receptor subtypes? Is Figure 3 showing heterotrimers with P2X6 receptor? A little explanation might be helpful.</p></disp-quote><p>We thank the reviewer for raising this important point. Indeed, it is well established that P2X6 does not form functional channels, which supports the conclusion that it does not form homotrimeric complexes. Although previous studies have shown that P2X6–GFP expression is generally lower, more diffuse, and not efficiently targeted to the cell surface compared with other P2X subtypes (see PMID: 12077178), the similar fluorescence distribution and density observed in our Figure 3 do not imply that P2X6 forms homotrimers.</p><p>We did not directly assess the presence of endogenous P2X6 in our HEK293T cells; however, according to the Human Protein Atlas, there is no detectable P2X6 RNA expression in HEK293 cells (nTPM = 0), indicating that endogenous P2X6 is not expressed in this cell line. To further investigate surface expression (see also point 2 of reviewer 1), we performed a commercial cell-surface protein biotinylation assay to assess whether GFP-tagged P2X6 reaches the plasma membrane. As expected, P2X6 was not detected at the cell surface in HEK293T cells, whereas GFP-tagged P2X1 to P2X5 were readily detected. These results further support the conclusion that P2X6 does not insert into the plasma membrane as a homotrimer, thereby validating our confocal fluorescence microscopy assay. These new data are now included in Figure 3 — figure supplement 1.</p><disp-quote content-type="editor-comment"><p>(5) It is easy to overlook the fact that the antagonist leaves the binding pocket once the biotin has been attached to the lysines. It might be helpful if the authors made this a little more apparent in Figure 1 or in the text describing the NASA chemistry reaction.</p></disp-quote><p>We thank the reviewer for this insightful suggestion. To address this, we have modified Figure 1A and updated the legend.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>This manuscript describes the development of a covalent labeling probe (X7-uP) that selectively targets and tags native P2X7 receptors at the plasma membrane of BV2 microglial cells. Using super-resolution imaging (dSTORM), the authors demonstrate that P2X7 receptors form nanoscale clusters upon microglial activation by lipopolysaccharide (LPS) and ATP, correlating with synergistic IL-1β release. These findings advance understanding of P2X7 reorganization during inflammation and provide a generalizable labeling strategy for monitoring endogenous P2X7 in immune cells.</p><p>Strengths:</p><p>(1) The authors designed X7-uP by coupling a high-affinity, P2X7-specific antagonist (AZ10606120) with N-cyanomethyl NASA chemistry to achieve site-directed biotinylation. This approach offers high specificity, minimal off-target reactivity, and a straightforward pull-down/imaging readout.</p><p>(2) The results connect P2X7's nanoscale clustering directly with IL-1β secretion in microglia, reinforcing the role of P2X7 in inflammation. By localizing endogenous P2X7 at single-molecule resolution, the authors reveal how LPS priming and ATP stimulation synergistically reorganize the receptor.</p><p>(3) The authors systematically validate their method in recombinant systems (HEK293 cells) and in BV2 cells, showing selective inhibition, mutational confirmation of the binding site, and Western blot pulldown experiments.</p></disp-quote><p>We thank the reviewer for their positive comment.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) While the data strongly indicate that P2X7 clustering contributes to IL-1β release, the manuscript would benefit from additional experiments (if feasible) or discussion on how receptor clustering interfaces with downstream inflammasome assembly. Clarification of whether the P2X7 clusters physically colocalize with known inflammasome proteins would solidify the mechanism.</p></disp-quote><p>We thank the reviewer for this valuable suggestion. Determining the physical colocalization of P2X7 clusters with known inflammasome components would provide important insight into the molecular partners involved in inflammasome activation. However, we believe that such an investigation would constitute a substantial study on its own and therefore lies beyond the scope of the present work.</p><p>Nevertheless, in response to the reviewer’s suggestion, we have added a short paragraph at the end of the Discussion section addressing potential mechanisms by which P2X7 clustering may contribute to downstream inflammasome activation. We also revised the text to tone down the hypothesis of physical colocalization.</p><disp-quote content-type="editor-comment"><p>(2) The authors might expand on the scope of X7-uP in other native cells that endogenously express P2X7 (e.g., macrophages, dendritic cells). Although they mention the possibility, demonstrating the probe's applicability in at least one other primary immune cell type would strengthen its general utility.</p></disp-quote><p>We thank the reviewer for this valuable suggestion. Again, we believe that such an investigation would constitute a substantial study on its own and therefore lies beyond the scope of the present work.</p><disp-quote content-type="editor-comment"><p>(3) The authors do include appropriate negative controls, yet providing additional details (e.g., average single-molecule on-time or blinking characteristics) in supplementary materials could help readers assess cluster calculations.</p></disp-quote><p>As suggested, we have included additional data showing single-molecule blinking events in untreated and LPS+ATP-treated BV2 cells, along with the corresponding movies. The data are now presented in Figure 5—supplement figure 3A and B and Figure 5—Videos 1 and 2.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) On line 96, the authors refer to the &quot;ballast&quot; domain of P2X7 receptor but do not cite the original article from which this nomenclature originated (McCarthy et al., 2019, Cell). This article should be cited to give appropriate credit.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>(2) On line 602, the authors state that they use models from PDB 1MK5 and 6U9W to generate the cartoons in Figure 6. The manuscripts from which these PDB files were generated need to be appropriately cited.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>(3) On line 319, the authors say &quot;300 mM BzATP&quot; but I think they mean 300 uM.</p></disp-quote><p>Done. Thank you for catching the typo.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Overall, excellent data quality. The paper would benefit from a discussion of the physiological implications of clustering. It would also be helpful to elaborate about the potential mechanisms for clustering: diffusion and/or insertion. Finally, the authors should comment on work by Mackinnon's (PMID: 39739811) and Santana lab (PMID: 31371391) on two distinct models for clustering of proteins.</p></disp-quote><p>As suggested by the reviewer, we have revised the discussion to incorporate their comments. First, we have added the following text:</p><p>“Upon BV2 activation, we observed significant nanoscale reorganization of P2X7. Both LPS and ATP (or BzATP) trigger P2X7 upregulation and clustering, increasing the overall number of surface receptors and the number of receptors per cluster, from one to three (Figure 6). By labeling BV2 cells with X7-uP shortly after IL-1b release, we were able to correlate the nanoscale distribution of P2X7 with the functional state of BV2 cells, consistent with the two-signal, synergistic model for IL-1b secretion observed in microglia and other cell types (Ferrari et al, 1996; Perregaux et al, 2000; Ferrari et al, 2006; Di Virgilio et al, 2017; He et al, 2017; Swanson et al, 2019). In this model, LPS priming leads to intracellular accumulation of pro-IL-1b, while ATP stimulation activates P2X7, triggering NLRP3 inflammasome activation and the subsequent release of mature IL-1b.</p><p>What is the mechanism underlying P2X7 upregulation that leads to an overall increase in surface receptors—does it result from the lateral diffusion of previously masked receptors already present at the plasma membrane, or from the insertion of newly synthesized receptors from intracellular pools in response to LPS and ATP? Although our current data do not distinguish between these possibilities, a recent study suggests that the a1 subunit of the Na<sup>+</sup>/K+-ATPase (NKAa1) forms a complex with P2X7 in microglia, including BV2 cells, and that LPS+ATP induces NKAa1 internalization (Huang et al, 2024). This internalization appears to release P2X7 from NKAa1, allowing P2X7 to exist in its free form. We speculate that the internalization of NKAa1 induced by both LPS and ATP exposes previously masked P2X7 sites, including the allosteric AZ10606120 sites, thus making them accessible for X7-uP labeling.”</p><p>Second, we have added a short paragraph at the end of the Discussion section addressing potential mechanisms by which P2X7 clustering may contribute to downstream inflammasome activation:</p><p>“What mechanisms underlie P2X7 clustering in response to inflammatory signals? Several models have been proposed to explain membrane protein clustering, including recruitment to structural scaffolds (Feng &amp; Zhang, 2009), partitioning into membrane domains enriched in specific chemical components such as lipid rafts (Simons &amp; Ikonen, 1997), and self-assembly mechanisms (Sieber et al, 2007). These self-assembly mechanisms include an irreversible stochastic model (Sato et al, 2019) and a more recent reversible self-oligomerization model which gives rise to higher-order transient structures (HOTS) (Zhang et al, 2025). Supported by cryogenic optical localization microscopy with very high resolution (~5 nm), the HOTS model has been observed in various membrane proteins, including ion channels and receptors (Zhang et al, 2025). Furthermore, HOTS are suggested to be dynamically modulated and to play a functional role in cell signaling, potentially influencing both physiological and pathological processes (Zhang &amp; MacKinnon, 2025). While this hypothesis is compelling, our current dSTORM data lack sufficient spatial resolution to confirm whether P2X7 trimers form HOTS via self-oligomerization. Further biophysical and ultra-high-resolution imaging studies are required to test this model in the context of P2X7 clustering.”</p></body></sub-article></article>